

1

2 Calsyntenin-3, an atypical cadherin, suppresses inhibitory basket- and  
3 stellate-cell synapses but boosts excitatory parallel-fiber synapses in  
4 cerebellum

5

6

7

8 Running title: Calsyntenin-3 controls cerebellar synapse formation

9

10

11 Zhihui Liu<sup>1,2\*</sup>, Man Jiang<sup>1,#</sup>, Kif Liakath-Ali<sup>1</sup>, Jaewon Ko<sup>3</sup>, Roger Shen Zhang<sup>1</sup>, and

12 Thomas C. Südhof<sup>1,2\*</sup>

13

14 <sup>1</sup>Department of Molecular and Cellular Physiology, and <sup>2</sup>Howard Hughes Medical  
15 Institute, Stanford University, Stanford, CA 94305, USA; <sup>3</sup>Department of Brain and  
16 Cognitive Sciences, Daegu Gyeongbuk Institute of Science and Technology, Daegu  
17 42988, Republic of Korea

18

19 #Present address: Department of Physiology, School of Basic Medicine and Tongji  
20 Medical College, Huazhong University of Science and Technology, Wuhan 430030,  
21 China

22 \*Correspondence: zhihuil@stanford.edu (Z.L.), tcs1@stanford.edu (T.C.S.)

23 **ABSTRACT**

24 Cadherins contribute to the organization of nearly all tissues, but the functions of several  
25 evolutionarily conserved cadherins, including those of calsyntenins, remain enigmatic.  
26 Puzzlingly, two distinct, non-overlapping functions for calsyntenins were proposed: As  
27 postsynaptic neurexin ligands in synapse formation, or as presynaptic adaptors for  
28 kinesin-mediated vesicular transport. Here, we show that acute CRISPR-mediated deletion  
29 of calsyntenin-3 in cerebellar Purkinje cells *in vivo* causes a large decrease in inhibitory  
30 synapses, but a surprisingly robust increase in excitatory parallel-fiber synapses. No  
31 changes in the dendritic architecture of Purkinje cells or in climbing-fiber synapses were  
32 detected. Thus, by promoting formation of an excitatory type of synapses and decreasing  
33 formation of an inhibitory type of synapses in the same neuron, calsyntenin-3 functions as a  
34 postsynaptic adhesion molecule that regulates the excitatory/inhibitory balance in Purkinje  
35 cells. No similarly opposing function of a synaptic adhesion molecule was previously  
36 observed, suggesting a new paradigm of synaptic regulation.

## 37 INTRODUCTION

38 Synapses mediate information transfer between neurons in brain, and process the  
39 information during transfer. In processing information, synapses are dynamic: Synapses  
40 are not only continuously restructured by various forms of synaptic plasticity, but are also  
41 eliminated and newly formed throughout life (Attardo et al., 2015; Pfeiffer et al., 2018).  
42 Synapse formation, elimination, and remodeling are thought to be organized by synaptic  
43 adhesion molecules (SAMs) (Südhof, 2021). Many candidate SAMs have been described,  
44 but most SAMs appear to make only partial contributions to the formation and specification  
45 of synapses. In particular, few SAMs were consistently found to contribute to the initial  
46 formation of synapses. At present, only adhesion-GPCR SAMs, such as latrophilins and  
47 BAls, are known to have a major impact on synapse numbers when tested using rigorous  
48 genetic approaches (Anderson et al., 2017; Bolliger et al., 2011; Kakegawa et al., 2015;  
49 Sando et al., 2019; Sando and Südhof, 2021; Sigoillot et al., 2015; Wang et al., 2020). In  
50 contrast, the majority of well-characterized SAMs, most prominently neurexins and  
51 LAR-type receptor phosphotyrosine phosphatases, appear to perform no major roles in  
52 establishing synaptic connections. Instead, these SAMs are essential for conferring onto  
53 synapses specific properties that differ between various types of synapses in a neural  
54 circuit (Chen et al., 2017; Emperador-Melero et al., 2021; Fukai and Yoshida, 2020; Missler  
55 et al., 2003; Sclip and Südhof, 2020).

56 Calsyntenins (a.k.a. alcadeins) are atypical cadherins that are encoded by three genes in  
57 mammals (*Clstn1-3* in mice) and a single gene in *Drosophila*, *C. elegans*, and other  
58 invertebrates (Araki et al., 2003; Hintsch et al., 2002; Ohno et al., 2014; Vogt et al., 2001).  
59 Calsyntenins are type I membrane proteins containing two N-terminal cadherin domains  
60 followed by a single LNS-domain (also referred to as LG-domain), a transmembrane region,  
61 and a short cytoplasmic tail. Calsyntenins are primarily expressed in neurons, although a  
62 calsyntenin-3 (*Clstn3*) variant with a different non-cadherin extracellular domain is present  
63 in adipocytes (referred to as *Clstn3 $\beta$* ; Zeng et al., 2019).

64 Two different views of calsyntenin functions have emerged. The first view posits that  
65 calsyntenins are postsynaptic adhesion molecules that bind to presynaptic neurexins to  
66 mediate both excitatory and inhibitory synapse formation, whereas the second view

67 proposes that calsyntenins are presynaptic adaptor proteins that mediate kinesin function in  
68 axonal transport. Extensive evidence supports both views.

69 In support of a role for calsynteins as a postsynaptic adhesion molecule, all calsyntenins  
70 were localized by immunoelectron microscopy to the postsynaptic densities of excitatory  
71 synapses in the cortex and cerebellum (Hintsch et al., 2002; Vogt et al., 2001). Moreover,  
72 calsyntenins induce presynaptic specializations in heterologous synapse formation assays  
73 when expressed in non-neuronal cells (Pettem et al., 2013). Most importantly, knockout  
74 (KO) mice of all three calsyntenins exhibit synaptic impairments (Kim et al., 2020; Lipina et  
75 al., 2016; Pettem et al., 2013; Ster et al., 2014). Careful analyses revealed that *Clstn3* KO  
76 mice exhibit a 20-30% decrease in excitatory synapse density in the CA1 region of the  
77 hippocampus (Kim et al., 2020; Pettem et al., 2013). In addition, Pettem et al. (2013)  
78 observed a similar decrease in inhibitory synapse density, although Kim et al. (2020) failed  
79 to detect the same decrease. Moreover, Pettem et al. (2013) detected a 30-40% decrease  
80 in mEPSC and mIPSC frequency, but unexpectedly found no change in excitatory synaptic  
81 strength as measured by input/output curves. The *Clstn2* KO also decreased the inhibitory  
82 synapse density in the hippocampus approximately 10-20% (Lipina et al., 2016), whereas  
83 the *Clstn1* KO modestly impaired excitatory synapses in juvenile but not in adult mice (Ster  
84 et al., 2014). Viewed together, these data suggest a postsynaptic role for calsyntenins in  
85 the hippocampus, although the modest effect sizes of the calsyntenin KO phenotypes were  
86 puzzling. Calsyntenins were proposed to function as postsynaptic adhesion molecules by  
87 binding to presynaptic neuexins, but distinct, mutually exclusive mechanisms of neuexin  
88 binding were described. Pettem et al. (2013) and Lu et al. (2014) showed that the LNS  
89 domain of calsyntenins binds to an N-terminal sequence of  $\alpha$ -neuexins that is not shared  
90 by  $\beta$ -neuexins. Kim et al. (2020), however, demonstrated that the cadherin domains of  
91 calsyntenins bind to the 6<sup>th</sup> LNS domain of neuexins that is shared by  $\alpha$ - and  $\beta$ -neuexins.  
92 Adding to this puzzle, Um et al. (2014) did not detect direct binding of calsyntenins to  
93 neuexins, and no study has reconstituted a stable calsyntenin-neuexin complex.

94 Similar to the hypothesis that calsyntenins act as postsynaptic adhesion molecules, the  
95 proposal that calsyntenins function as presynaptic kinesin-adaptor proteins that facilitate  
96 vesicular transport is also based on extensive studies. This proposal focuses on the  
97 transport of vesicles containing APP (Araki et al., 2007; Konecna et al., 2006; Vagnoni et al.,

98 2012). A cytoplasmic sequence of calsyntenins binds to kinesins (Konecna et al., 2006),  
99 and at least *Clstn1* is localized to transport vesicles containing kinesin (Ludwig et al., 2009).  
100 Moreover, carefully controlled immunoprecipitations showed that calsyntenins are present  
101 in a molecular complex with presynaptic GABA<sub>B</sub>-receptors and APP (Dinamarca et al.,  
102 2019; Schwenk et al., 2016). However, *Clstn1* KO mice exhibit only modest changes in  
103 APP transport or the proteolytic processing of APP into A $\beta$  peptides, while *Clstn2* KO mice  
104 display no change (Gotoh et al., 2020). Furthermore, the *Clstn1* KO simultaneously  
105 increased the levels of the C-terminal cleavage fragment (CTF) of APP and of A $\beta$  peptides  
106 without changing APP levels, making it difficult to understand how a decreased APP  
107 cleavage causing increased CTF levels could also elevate A $\beta$  levels (Gotoh et al., 2020).  
108 As a result, the kinesin binding, APP interaction, and GABA<sub>B</sub>-receptor complex formation by  
109 calsyntenins seem well established, but it is not yet clear how these activities converge on a  
110 function in axonal transport of APP.

111 The two divergent views of the function of calsyntenins, although well supported, are  
112 difficult to reconcile with each other. Given the potential importance of calsyntenins, we  
113 here pursued an alternative approach to study their functions. We aimed to identify neurons  
114 that express predominantly one calsyntenin isoform in order to avoid potential redundancy,  
115 and then examined the function of that calsyntenin isoform using acute genetic ablations  
116 and synapse-specific electrophysiological analyses. Our results reveal that cerebellar  
117 Purkinje cells express only *Clstn3* at high levels. Using CRISPR/Cas9-mediated deletions,  
118 we unexpectedly found that the *Clstn3* KO in Purkinje cells upregulated excitatory  
119 parallel-fiber synapses and had no effect on excitatory climbing-fiber synapses, but  
120 suppressed inhibitory basket- and stellate-cell synapses. These results indicate that a  
121 particular synaptic adhesion molecule can support formation of one class of synapses but  
122 suppress formation of another class of synapses in the same neuron.

## 123 RESULTS

124 ***Clstn3* is the predominant calsynenin isoform in cerebellar Purkinje cells.** To analyze  
125 physiologically relevant functions of calsynenins, we aimed to identify a type of neuron that  
126 expresses a particular calsynenin isoform at much higher levels than others. This was  
127 necessary to avoid functional redundancy among multiple calsynenins. Since most  
128 previous studies on calsynenin functions were performed in the hippocampus (Kim et al.,  
129 2020; Lipina et al., 2016; Pettem et al., 2013; Ster et al., 2014), we examined calsynenin  
130 expression in the hippocampus using single-molecule *in situ* hybridizations. All three  
131 calsynenins were expressed in the CA1 and CA3 regions and the dentate gyrus. In the  
132 CA1 region, *Clstn1* and *Clstn3* levels were highest, in the CA3 region all three calsynenins  
133 were similarly abundant, and in the dentate gyrus, *Clstn1* and *Clstn2* were most strongly  
134 present (Figure 1A). These results suggest that most hippocampal neurons co-express  
135 multiple calsynenin isoforms, which may account for the modest phenotypes observed with  
136 *Clstn1*, *Clstn2*, and *Clstn3* KO mice (Kim et al., 2020; Lipina et al., 2016; Pettem et al., 2013;  
137 Ster et al., 2014).

138 We next examined the cerebellum because single-cell RNA transcriptome databases  
139 suggested that in the cerebellum, granule cells express primarily *Clstn1*, while Purkinje  
140 cells express *Clstn3* (Peng et al., 2019; Saunders et al., 2018; Schaum et al., 2018; Tasic et  
141 al., 2018; Zeisel et al., 2018). Indeed, single-molecule *in situ* hybridization in cerebellar  
142 sections demonstrated that the expression of calsynenin isoforms was much more  
143 segregated in cerebellum than in the hippocampus (Figure 1B). Purkinje cells express  
144 almost exclusively *Clstn3*, although low amounts of *Clstn2* were also detectable, whereas  
145 granule cells express *Clstn1* (Figure 1C). The differential labeling signal for the calsynenins  
146 in the cerebellum was not due to differences in probe efficiency because in the  
147 hippocampus, the same probes under the same conditions produced equally strong signals  
148 (Figure 1A). Since Purkinje cells represent an excellent experimental system for synaptic  
149 physiology, we decided to focus on the function of *Clstn3* in these neurons.

150 ***In vivo* CRISPR efficiently deletes *Clstn3* in cerebellar Purkinje cells, causing major**  
151 **impairments in motor learning.** Advances in CRISPR-mediated genetic manipulations  
152 suggest that it is possible to dissect a gene's function using acute CRISPR-mediated  
153 deletions *in vivo* (Incontro et al., 2014). When we tested multiple single guide RNAs

154 (sgRNAs) for the *Clstn3* gene, we identified two sgRNAs targeting exons 2 and 3 of the  
155 *Clstn3* gene that were highly efficacious in suppressing *Clstn3* expression in Purkinje cells  
156 *in vivo* (Figure 2A-2G). AAVs encoding the sgRNAs and tdTomato (as an expression  
157 marker) were stereotactically injected at P21 into the cerebellum of mice that constitutively  
158 express *spCas9* (Platt et al., 2014), and mice were analyzed at ~P50 by quantitative  
159 RT-PCR (Figure 2C, 2D). The *Clstn3* CRISPR KO was highly effective, decreasing *Clstn3*  
160 mRNA levels by >60% (Figure 2D, 2E). Immunoblotting confirmed the loss of ~80% of  
161 *Clstn3* protein after the *Clstn3* CRISPR KO (Figure 2F). We also examined *Clstn1* and  
162 *Clstn2* expression by immunoblotting, using an antibody that reacts with both isoforms and  
163 additionally recognizes non-specific bands, but found no change (Figure S1). Analysis of  
164 the *Clstn3* CRISPR KO for potential off-target effects demonstrated that at the sites most  
165 similar to the *Clstn3* target sequence, no mutations were detected (Figure S2). Viewed  
166 together, these data indicate that the cerebellar *Clstn3* CRISPR KO effectively ablates  
167 *Clstn3* expression in cerebellar neurons.

168 To explore the functional consequences of the *Clstn3* KO in Purkinje cells, we analyzed its  
169 effect on the motor behavior of mice. Strikingly, the cerebellar *Clstn3* KO nearly abolished  
170 motor learning of the mice, as assayed with the rotarod task (Figure 2G). A behavioral test  
171 measuring social interactions did not reveal significant changes (Figure S3), suggesting  
172 that the mice were not broadly impaired. Thus, the *Clstn3* KO in the cerebellum likely  
173 impairs cerebellar functions in a specific manner. The motor coordination deficit in *Clstn3*  
174 CRISPR KO mice is consistent with phenotypes observed in constitutive *Clstn3* KO mice  
175 ([www.mousephenotype.org](http://www.mousephenotype.org)) (Dickinson et al., 2016), suggesting that our CRISPR KO  
176 approach is reliable and specific.

### 177 **The *Clstn3* KO in Purkinje cells impairs inhibitory synapses in the cerebellar cortex.**

178 To test whether the *Clstn3* KO affected inhibitory synapses on Purkinje cells, we examined  
179 the inhibitory synapse density in the cerebellar cortex using immunocytochemistry for vGAT,  
180 an inhibitory synapse marker (Figure 3A). The CRISPR KO of *Clstn3* in Purkinje cells  
181 robustly reduced the inhibitory synapse density in the molecular layer, Purkinje-cell layer,  
182 and granule-cell layer of the cerebellar cortex (Figure 3B-3D). The most extensive decrease  
183 (~60%) was observed in the deep molecular layer (Figure 3B), where we also detected a  
184 significant reduction (~25%) in the size of vGAT-positive puncta (Figure 3C). vGAT-positive

185 synapses in Purkinje cell and granule cell layers were less affected (~20% reduction; Figure  
186 3D).

187 The decrease in inhibitory synapse density raises the question whether inhibitory synaptic  
188 transmission is suppressed. To address this question, we recorded miniature inhibitory  
189 postsynaptic currents (mIPSCs) from Purkinje cells in the presence of tetrodotoxin (Figure  
190 4). *Clstn3* KO produced a large decrease in mIPSC frequency (~60%), without changing  
191 the mIPSC amplitude (Figure 4A-4C). Moreover, the *Clstn3* KO increased the rise but not  
192 decay times of mIPSCs (Figure 4D). Measurements of the Purkinje cell capacitance and  
193 input resistance showed that the *Clstn3* deletion did not produce major changes,  
194 demonstrating that it did not globally alter Purkinje cell properties (Figure S4A).

195 mIPSCs are heterogeneous in Purkinje cells. Smaller mIPSCs are mostly derived from  
196 more distant stellate-cell synapses, and larger mIPSCs from more proximal basket-cell  
197 synapses (Nakayama et al., 2012). To examine these two types of input synapses  
198 separately, we plotted the mIPSC amplitudes in a normal distribution (Figure 4E). This plot  
199 revealed that the majority of mIPSC amplitudes (>90%) are <60 pA. Therefore, we  
200 separately analyzed mIPSCs with amplitudes of >60 pA and <60 pA, of which the >60 pA  
201 mIPSCs likely represent basket cell mIPSCs, whereas the <60 pA mIPSCs are composed  
202 predominantly (but not exclusively) of stellate cell mIPSCs. Both classes of mIPSCs  
203 exhibited similar impairments in frequency and kinetics, although the changes were more  
204 pronounced for larger mIPSCs (Figure 4F-4H; S5). These results are consistent with the  
205 morphological data suggesting a larger decrease in basket cell synapses than in stellate  
206 cell synapses (Figure 3A-3D).

207 Does the change in inhibitory synapse density and mIPSCs cause a change in overall  
208 inhibitory synaptic strength? We examined evoked inhibitory synaptic responses, using  
209 extracellular stimulations of basket cell axons close to the Purkinje cell layer (Figure 5A).  
210 We detected a significant decrease (~40%) in IPSC amplitudes. The decrease in IPSC  
211 amplitude is consistent with a loss of inhibitory synapses, but could also be due to a  
212 decrease in release probability. However, we detected no major changes in the coefficient  
213 of variation, paired-pulse ratio, or kinetics of evoked IPSCs, suggesting that the release  
214 probability is normal (Figure 5B-5F, S4B). These data confirm the morphological results,  
215 suggesting that the *Clstn3* KO decreases inhibitory synapse numbers.



216 ***Clstn3* deletion in Purkinje cells increases excitatory parallel-fiber but not**  
217 **climbing-fiber synapse densities.** The decrease in inhibitory synapse numbers by the  
218 *Clstn3* KO is consistent with previous studies suggesting that *Clstn3* promotes synapse  
219 formation in the hippocampus, but these previous studies primarily identified a decrease in  
220 excitatory synapses (Kim et al., 2020; Pettem et al., 2013; Ranneva et al., 2020). We thus  
221 tested whether the *Clstn3* KO also affects excitatory synapse numbers in cerebellum.  
222 Purkinje cells receive two different excitatory synaptic inputs with distinct properties:  
223 Parallel-fiber synapses that are formed by granule cells on distant Purkinje cell dendrites,  
224 and climbing-fiber synapses that are formed by inferior olive neurons on proximal Purkinje  
225 cell dendrites. Parallel-fiber synapses use the vesicular glutamate transporter vGluT1,  
226 whereas climbing-fiber synapses use the vesicular glutamate transporter vGluT2 (Hioki et  
227 al., 2003). Moreover, parallel-fiber synapses are surrounded by processes formed by  
228 Bergmann astroglial cells, creating a tripartite synapse in which the glial processes contain  
229 high levels of GluA1 (Baude et al., 1994). As a first step towards assessing the effect of the  
230 *Clstn3* KO on excitatory synapses on Purkinje cells, we analyzed cerebellar sections from  
231 control and *Clstn3* KO mice by immunohistochemistry for vGluT1, vGluT2 and GluA1  
232 (Figure 6).

233 Confocal microscopy of cerebellar cortex sections immunolabeled for vGluT1 revealed  
234 intense staining that, surprisingly, was enhanced by the *Clstn3* deletion in Purkinje cells  
235 (Fig. 6A). Because parallel-fiber synapses in the cerebellar cortex are so numerous that  
236 confocal microscopy cannot resolve individual vGluT1-positive synaptic puncta, we  
237 measured the overall vGluT1 staining intensity as a proxy for synapse density (Figure 6A)  
238 (Zhang et al., 2015). The *Clstn3* deletion in Purkinje cells caused a robust increase (~25%)  
239 in the vGluT1 staining intensity of both the superficial and the deep molecular layers of the  
240 cerebellar cortex (Figure 6B).

241 The potential increase in parallel-fiber synapses induced by the *Clstn3* KO, suggested by  
242 the enhanced vGluT1 staining intensity, is unexpected. This prompted us to examine the  
243 levels of GluA1 as an astroglial marker of tripartite parallel-fiber synapses (Figure 6C;  
244 Baude et al., 1994). Again, the *Clstn3* KO in Purkinje cells induced a significant increase  
245 (~25%) in synaptic GluA1 staining intensity (Figure 6D), consistent with the increase in  
246 vGluT1 staining intensity.

247 We next analyzed the density of climbing-fiber synapses by staining cerebellar sections for  
248 vGluT2, but detected no significant effect of the *Clstn3* KO in Purkinje cells (Figure 6E).  
249 Different from parallel-fiber synapses that contain vGluT1, climbing-fiber synapses are  
250 labeled with antibodies to vGluT2 and are readily resolved by confocal microscopy (Figure  
251 6E). The number and size of synaptic puncta identified with vGluT2 antibodies were not  
252 altered by the *Clstn3* KO, although there was a slight trend towards a decrease in  
253 climbing-fiber synapse density (Figure 6F, 6G). These observations suggest that the  
254 enhancement of parallel-fiber synapse density by the *Clstn3* KO is specific for this type of  
255 synapse.

256 **The *Clstn3* KO increases the spine density of Purkinje cells.** It is surprising that the  
257 *Clstn3* KO in Purkinje cells appears to increase the parallel-fiber synapse density, as one  
258 would expect a synaptic adhesion molecule to promote but not to suppress formation of a  
259 particular synapse. The parallel-fiber synapse increase is likely not a homeostatic response  
260 to the loss of inhibitory synapses because such a response, which would aim to maintain  
261 the correct excitatory/inhibitory balance, should involve a decrease, and not an increase, in  
262 parallel-fiber synapses. The increase in parallel-fiber synapse numbers is also unexpected  
263 given previous results showing that in hippocampal CA1 neurons, the *Clstn3* KO decreases  
264 excitatory synapse numbers (Kim et al., 2020; Pettem et al., 2013). To independently  
265 confirm this increase, we analyzed the dendritic spine density in Purkinje cells. Since nearly  
266 all spines contain parallel-fiber synapses and all parallel-fiber synapses are on spines  
267 (Sotelo, 1975), the spine density of Purkinje cells represents a reliable proxy for synapse  
268 density.

269 We filled individual Purkinje cells in acute slices with biocytin via a patch-pipette, and  
270 analyzed their dendritic structure and spine density by quantitative morphometry (Figure 7A,  
271 S6A, S6B). Reconstructions of 6 Purkinje cells from control and *Clstn3* KO mice revealed a  
272 trend towards an increased dendrite length in *Clstn3*-deficient Purkinje cells without a  
273 significant change in dendritic architecture, demonstrating that the *Clstn3* KO does not  
274 impair the overall structure of Purkinje cells (Figure 7B). Quantification of dendritic spines  
275 uncovered in *Clstn3*-deficient Purkinje cells a robust increase (~30%) in the density of  
276 spines in the superficial area of the cerebellar cortex, and a trend towards an increase in  
277 the deep area of the cerebellar cortex (Figure 7C-7F). The increase in spine density was

278 particularly pronounced for thin spines (Figure 7G; S6C, S6D). These findings provide  
279 independent evidence that the *Clstn3* KO increases the parallel-fiber synapse density, and  
280 precisely mirror those obtained by analyzing the vGluT1- and GluA1-staining intensity of the  
281 cerebellar cortex (Figure 6A-6D).

282 **The *Clstn3* KO increases parallel-fiber but not climbing-fiber synaptic transmission.**

283 The increase in parallel-fiber synapses could be due to a true enhancement of parallel-fiber  
284 synapse formation, or a compensatory reaction to a decrease in parallel-fiber synapse  
285 function. Although the latter hypothesis would be consistent with a homeostatic response, it  
286 seems unlikely given that in vertebrates, synapses rarely proliferate in response to a  
287 functional impairment. To clarify this question, we analyzed parallel-synapse function by  
288 electrophysiology, and compared it to climbing-fiber synapse function as an internal control  
289 since climbing-fiber synapse numbers are not changed by the *Clstn3* KO in Purkinje cells.

290 We first monitored spontaneous miniature synaptic events (mEPSCs) in the presence of  
291 tetrodotoxin. We observed an increase in mEPSC amplitudes (~25%) and frequency (~15%)  
292 in *Clstn3* KO neurons, without a notable change in mEPSC kinetics (Figure 8A-8D). Most  
293 mEPSCs in Purkinje cells are derived from parallel-fiber synapses. Because of the large  
294 dendritic tree of Purkinje cells, synapses on distant dendrites produce slower and smaller  
295 mEPSCs than synapses on proximal dendrites (Zhang et al., 2015). To ensure that we  
296 were monitoring mEPSCs derived from parallel-fiber synapses (whose density is increased  
297 morphologically), we analyzed only slow mEPSCs with rise times of >1 ms that are mostly  
298 generated by parallel-fiber synapses on distant dendrites (Nakayama et al., 2012;  
299 Yamasaki et al., 2006). The results were the same as for total mEPSCs, confirming that the  
300 *Clstn3* KO increases parallel-fiber synaptic activity (Figure 8E-8H).

301 Finally, we measured evoked parallel-fiber EPSCs, using input-output curves to correct for  
302 variations in the placement of the stimulating electrode (Figure 9A). Consistent with the  
303 morphological and mEPSC data, the *Clstn3* KO robustly enhanced parallel-fiber synaptic  
304 responses (~60% increase) (Figure 9B-9D). This finding suggests that the *Clstn3* KO not  
305 only increases the density of parallel-fiber synapses, but also renders these synapses more  
306 efficacious. The increased strength of parallel-fiber synaptic transmission was not due to a  
307 change in release probability because neither the coefficient of variation nor the  
308 paired-pulse ratios of parallel-fiber EPSCs were affected (Figure 9E-9G). The increase of

309 parallel-fiber EPSCs is consistent with the vGluT1 intensity and mEPSC amplitude changes,  
310 providing further evidence that the *Clstn3* KO enhances parallel-fiber synapses.

311 In contrast to parallel-fiber EPSCs, climbing-fiber EPSCs exhibited no *Clstn3* KO-induced  
312 alteration. Specifically, the amplitude, paired-pulse ratio, and kinetics of climbing-fiber  
313 EPSCs in control and *Clstn3* KO Purkinje cells were indistinguishable (Figure 9H-9L).  
314 These findings are consistent with the lack of a change in vGluT2-positive synaptic puncta  
315 analyzed morphologically (Figure 6E-6G). Viewed together, these data suggest that *Clstn3*  
316 KO produces an increase in excitatory parallel-fiber, but not climbing-fiber, synapses.

317

## 318 **DISCUSSION**

319 Calsyntenins are intriguing but enigmatic cadherins, a class of diverse adhesion molecules  
320 that generally function as tissue organizers. Two distinct, non-overlapping roles were  
321 proposed for calyntenins, as a postsynaptic adhesion molecule promoting synapse  
322 formation and as a kinesin-adaptor protein mediating axonal and dendritic transport, in  
323 particular of APP (Araki et al., 2007; Kim et al., 2020; Konecna et al., 2006; Lipina et al.,  
324 2016; Pettem et al., 2013; Ster et al., 2014; Vagnoni et al., 2012). Both functions are  
325 supported by extensive data, but neither function was conclusively tested. Here, we  
326 examined the role of one particular calyntenin, *Clstn3*, in one particular neuron, Purkinje  
327 cells that predominantly express this calyntenin isoform. Our data establish that *Clstn3*  
328 acts as a postsynaptic adhesion molecule in Purkinje cells that is selectively essential for  
329 regulating synapse numbers, confirming an essential function for *Clstn3* as a synaptic  
330 adhesion molecule. Our data are surprising in revealing that *Clstn3* functions not by  
331 universally promoting synapse formation, but by exerting opposite effects in different types  
332 of synapses. Specifically, our results demonstrate that deletion of *Clstn3* causes a  
333 decrease in inhibitory basket- and stellate-cell synapses on Purkinje cells, but an increase  
334 in excitatory parallel-fiber synapses (Figure S7). Thus, *Clstn3* doesn't function simply as a  
335 synaptogenic adhesion molecule, but as a regulator of the balance of excitatory and  
336 inhibitory synaptic inputs on Purkinje cells.

337 The functions we describe here for *Clstn3* are different from those of previously identified  
338 synaptic adhesion molecules or synapse-organizing signals. Whereas presynaptic  
339 adhesion molecules generally act in both excitatory and inhibitory synapses, few

340 postsynaptic adhesion molecules were found to function in both. In the rare instances in  
341 which an adhesion molecule was documented to mediate signaling in excitatory and  
342 inhibitory synapses, such as the case of *Nlgn3* (but not of other neuroligins), it acts to  
343 promote synaptic function in both (Chanda et al., 2017; Zhang et al., 2015). Not only do we  
344 find that *Clstn3*, different from previously identified synaptic adhesion molecules, restricts  
345 formation at a specific synapse (parallel-fiber synapses), but also that *Clstn3* enhances  
346 formation of another specific synapse (GABAergic basket- and stellate-cell synapses) in the  
347 same neurons.

348 Several questions arise. First, why are the phenotypes we observe in *Clstn3* KO Purkinje  
349 cells so much stronger than those previously detected in CA1-region pyramidal neurons  
350 (Kim et al., 2020; Pettem et al., 2013)? This difference could be due to differences in cell  
351 type or to the more acute nature of our manipulations. More likely, however, this  
352 difference is caused by the lack of redundancy of *Clstn3* function in Purkinje cells since  
353 other calsynenin isoforms are co-expressed with *Clstn3* in CA1-region neurons (Figure 1A),  
354 but not in Purkinje cells (Figure 1B, 1C).

355 Second, what is the mechanism of *Clstn3* action at synapses? We used manipulations in  
356 young adult mice in which cerebellar synapses are not yet completely established and in  
357 which synapse formation and elimination likely occurs continuously (Attardo et al., 2015;  
358 Pfeiffer et al., 2018). At present, our data do not reveal whether *Clstn3* acts in the initial  
359 establishment and/or the maintenance of synapses, a somewhat artificial distinction since  
360 synapse formation may actually consist in the stabilization of promiscuous contacts and  
361 synapses turn over continuously (Südhof, 2021). The functional consequences of these  
362 actions for cerebellar circuits are identical, in that both lead to a dramatic shift in  
363 excitatory/inhibitory balance in the cerebellar cortex.

364 Third, what trans-synaptic interactions mediate the functions of *Clstn3*? Several papers  
365 describe binding of calsynenins to neurexins (Kim et al., 2020; Pettem et al., 2013).  
366 However, our data uncover a phenotype that is different from that observed with deletions  
367 of neurexins or neurexin ligands, suggesting that *Clstn3* does not function exclusively by  
368 binding to neurexins. The deletion of the neurexin ligand *Cbln1* leads to a loss of  
369 parallel-fiber synapses in the cerebellar cortex instead of a gain, suggesting that a different  
370 calsynenin ligand is involved. Moreover, the specific conclusions of the papers describing

371 calyntenin-binding to neuroligins differ (Kim et al., 2020; Pettem et al., 2013), leaving the  
372 interaction mode undefined. Thus, we believe the most parsimonious hypothesis is that  
373 postsynaptic calyntenins function by binding to presynaptic ligands other than neuroligins  
374 that remain to be identified.

375 Fourth, does *Clstn3* physiologically act to restrict the formation of excitatory parallel-fiber  
376 synapses, leading to an increase in parallel-fiber synapses upon deletion of *Clstn3*, or is  
377 this increase an indirect compensatory effect produced by the decrease in inhibitory  
378 synapses? Multiple arguments support a specific action of *Clstn3* at parallel-fiber synapses.  
379 *Clstn3* protein was localized to parallel-fiber synapses by immunoelectron microscopy  
380 (Hintsch et al., 2002). Moreover, other genetic manipulations that cause a decrease in  
381 inhibitory synaptic transmission in cerebellar cortex, such as deletions of *Nlgn2* or of  
382 GABA<sub>A</sub>-receptors (Briatore et al., 2020; Fritschy et al., 2006; Meng et al., 2019; Zhang et al.,  
383 2015), do not induce an increase in excitatory parallel-fiber synapses. Finally and probably  
384 most importantly, although competition between synapses using the same transmitters is  
385 well-described (e.g., competition between glutamatergic parallel- and climbing-fiber  
386 synapses on Purkinje cells; Cesa and Strata, 2009; Miyazaki et al., 2012; Strata et al.,  
387 1997), no such competition has been observed between GABAergic and glutamatergic  
388 synapses, such that the decrease in one of them would lead to the increase of the other.  
389 Quite the contrary, the rules of homeostatic plasticity would predict that a decrease in  
390 GABAergic synapses should lead to a decrease, not an increase, in glutamatergic  
391 synapses (Monday et al., 2018; Nelson and Valakh, 2015). Thus, our data overall suggest  
392 that *Clstn3* specifically acts to limit the formation of parallel-fiber synapses and enhance the  
393 formation of inhibitory synapses in the cerebellar cortex.

394 Our study also has clear limitations. We did not examine axonal or dendritic transport, and  
395 cannot exclude the possibility that *Clstn3* performs an additional function as an adaptor for  
396 kinesin-mediated transport. Moreover, we cannot rule out the possibility that different  
397 calyntenins perform distinct functions. In addition, although the postsynaptic functions of  
398 *Clstn3* in Purkinje cell synapses strongly argue against a neuroligin-dependent mechanism,  
399 our data do not exclude the possibility that calyntenins perform other functions in other  
400 neurons in a neuroligin-dependent manner. The example of neuroligins shows that a

401 synaptic adhesion molecule can have both a neurexin-dependent and  
402 neurexin-independent functions (Ko et al., 2009; Wu et al., 2019).

403 Multiple synaptic adhesion molecules have already been implicated in synapse formation in  
404 Purkinje cells. The interaction of presynaptic neurexins with cerebellins and postsynaptic  
405 GluD receptors plays a major role in shaping parallel-fiber synapses (Yuzaki and Aricescu,  
406 2017), and the binding of C1ql1 to postsynaptic Bai3 has a prominent function in  
407 climbing-fiber synapses (Kakegawa et al., 2015; Sigoillot et al., 2015). Postsynaptic *Nlgn2*  
408 and *Nlgn3* are major contributors to the function of GABAergic synapses in Purkinje cells  
409 (Zhang et al., 2015), as is dystroglycan (Briatore et al., 2020). How can we envision the  
410 collaboration of various synaptic adhesion complexes in establishing and shaping the  
411 different types of synapses on Purkinje cells? Do these molecules act sequentially at  
412 different stages, collaborate, or work in parallel? The overall view of synapse formation that  
413 emerges from these studies resembles a conductorless orchestra, in which different  
414 players individually contribute distinct essential facets to the work that is being performed.  
415 In this orchestra, some players, such as neurexins, play prominent roles in coordinating the  
416 actions of their sections, whereas others, such as latrophilins, initiate movements. In this  
417 scenario, *Clstn3* (and possibly other calsyntenins) may regulate the loudness of different  
418 sections of the orchestra, or translated into the terms of a synapse, control the efficacy of  
419 signals regulating excitatory vs. inhibitory synapses.

420 **METHODS**421 **Key resources table**

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Genetic reagent (Mus musculus)	Constitutive Cas9	PMID: 25263330	JAX ID: 024858	
Cell line (Homo sapiens)	HEK293T	ATCC	CRL-11268	
Recombinant DNA reagent	AAV-U6-sg66-U6-sg21-CAG tdTomato	This paper		Serotyped with AAV-DJ
Sequencebased reagent	Clstn1 RNA FISH probe	Advanced Cell Diagnostics	Cat: 542611	
Sequencebased reagent	Clstn2 RNA FISH probe	Advanced Cell Diagnostics	Cat: 542621	
Sequence based reagent	Clstn3 RNA FISH probe	Advanced Cell Diagnostics	Cat: 542631	
Sequence based reagent	Clstn3 qPCR primers and probe	This paper		
Antibody	Anti-pan Clstn1/2 rabbit polyclonal	PMID: 24613359		1:1000 IB
Antibody	Clstn3 rabbit polyclonal	PMID: 24613359		1:1000 IB
Antibody	Anti-ACTB mouse monoclonal	Sigma	#A1978	1:10000 IB
Antibody	IRDye® 680LT Donkey anti-Rabbit	LI-COR	926-68023	1:10000 IB
Antibody	IRDye® 800CW donkey anti-mouse	LI-COR	926-32212	1:10000 IB



Antibody	Anti-vGluT1 rabbit polyclonal	Yenzym	YZ6089	1:1000 IHC
Antibody	Anti-vGluT2 rabbit polyclonal	Yenzym	YZ6097	1:1000 IHC
Antibody	Anti-vGAT guinea pig polyclonal	Sysy	131004	1:1000 IHC
Antibody	Alexa goat anti guinea pig 633	Invitrogen	A-21105	1:1000 IHC
Antibody	Alexa goat anti rabbit 647	Invitrogen	A-21245	1:1000 IHC
Chemical compound, drug	Tribromoethanol	Sigma	T48402	250 mg/kg for anesthesia
Chemical compound, drug	Picrotoxin	Tocris	1128	
Chemical compound, drug	APV	Tocris	0106	
Chemical compound, drug	CNQX	Tocris	1045	
Chemical compound, drug	NBQX	Tocris	1044	
Chemical compound, drug	Tetrodotoxin	Cayman Chemical	14964	
Chemical compound, drug	DAPI	Sigma	D8417	
Chemical compound, drug	Biocytin	Sigma	B4261	
Software, algorithm	SnapGene	GSL Biotech		previously existing
Software, algorithm	Image Studio Lite	LI-COR		previously existing
Software, algorithm	pClamp10	Molecular Device		previously existing
Software, algorithm	Clampfit10	Molecular Device		previously existing
Software, algorithm	NIS-Elements AR	Nikon		previously existing
Software, algorithm	ImageJ	National Institutes of Health		previously existing
Software, algorithm	Neurolucida360	MBF science		previously existing

Software, algorithm	Adobe Illustrator	Adobe		previously existing
Software, algorithm	Graphpad Prism 8.0	Graphpad software		previously existing

422 IB: immunoblotting, IHC: immunohistochemistry

423

424 **Animals**

425 Constitutive Cas9 mice (<https://www.jax.org/strain/024858>) were used and maintained as  
426 homozygotes (Platt et al., 2014). Analyses were performed on littermate mice. Mice were  
427 fed ad libitum and on 12 hour light dark cycles. All protocols were carried out under National  
428 Institutes of Health *Guidelines for the Care and Use of Laboratory Animals* and were  
429 approved by the Administrative Panel on Laboratory Animal Care at Stanford University.

430

431 **Single molecule RNA fluorescent in-situ hybridization (smRNA-FISH)**

432 smRNA-FISH in-situ hybridization experiment was performed on brain sections from P30  
433 wild type C57BL/6J mice according to the manufacturer instructions using Multiplex  
434 Fluorescent Detection Reagents V2 kit (# 323110, Advanced Cell Diagnostics).  
435 Predesigned probes for Clstn1 (# 542611), Clstn2 (# 542621), and Clstn3 (# 542631) were  
436 purchased from ACD.

437

438 **SgRNA design and generation of Vectors**

439 SgRNAs were designed using protocols developed by the Zhang lab  
440 (<https://zlab.bio/guide-design-resources>) to minimize potential off-target effects. The pAAV  
441 construct was modified from Addgene #60231 (Platt et al., 2014) with Cre-GFP replaced by  
442 tdTomato and human synapsin by CAG promoter to allow efficient expression in the  
443 cerebellum. Two sgRNAs were cloned in a single vector using Golden Gate Cloning  
444 assembly. Empty vector without sgRNAs was used as control. Genome editing efficiency of  
445 sgRNAs was initially evaluated using TIDE (<https://tide.nki.nl/>) (Brinkman et al., 2014).

446 Potential off-target editing sites were chosen from predictions while design. Forward and  
447 reverse primers were designed to flank sgRNAs, and PCR product of Genomic DNA were  
448 sequenced and compared on TIDE.

449 Primers for off-target site sequencing on sg66:

Chromosome	Forward primer	Reverse primer
chr7	GAACCCCAAGTACGCCAAGA	TTGACAGTGTGTGGCTGTGT
chr2	TGCTCCGAGGTCTCCCTAAA	AAGGTTCCAGGTCCTGTTGC
chr13	AAGAGATCCCTCCGAACATGG	GCCCATCTGACAGGAGTATGT

450

451 Primers for off-target site sequencing on sg21:

Chromosome	Forward primer	Reverse primer
chr17	GGCAGATCTCTCGTGATGGC	TTAGTCTTGGCTGCGTCACC
chr5	GGAACAAAAGCCTGGCTCC	AATCTGGGCTGGCTCATTCC
chr13	AGAGAAGGGAATGGGACCGA	ATGGCTCAGCGATTAGTGGG

452

### 453 **AAV preparation and stereotactic Injections**

454 pAAV carrying sgRNAs was serotyped with the AAV-DJ capsid (Grimm et al., 2008). Briefly,  
455 helper plasmids (phelper and pDJ) and AAV-sgRNA vector were co-transfected into  
456 HEK293T cells (ATCC, CRL-11268), at 4 µg of each plasmid per 30 cm<sup>2</sup> culture area, using  
457 the calcium phosphate method. Cells were harvested 72 h post-transfection, and nuclei  
458 were lysed and AAVs were extracted using a discontinuous iodixanol gradient media at  
459 65,000 rpm for 3 h. AAVs were then washed and dialyzed in DMEM and stored at -80 °C  
460 until use. Genomic titer was tested with qPCR and adjusted to 5 x 10<sup>12</sup> particles/ml for *in*  
461 *vivo* injections.

462 P21 Cas9 mice were anesthetized with tribromoethanol (250 mg/kg, T48402, Sigma, USA),  
463 head-fixed with a stereotaxic device (KOPF model 1900). AAVs carrying sgRNAs or control  
464 viruses were loaded via a glass pipette connected with a 10 µl Hamilton syringe (Hamilton,  
465 80308, US) on a syringe injection pump (WPI, SP101I, US) and injected at a speed of 0.15  
466 µl/min. Pipette was left in cerebellum for additional 5 min after injection completion.  
467 Carprofen (5 mg/kg) was injected subcutaneously as anti-analgesic treatment. To infect the  
468 whole cerebellum, we injected multiple sites evenly distributing over the cerebellum skull,  
469 coordinates were as previously reported (Zhou et al., 2020), anterior to bregma, lateral to  
470 midline, ventral to dura (mm): (-5.8,±0.75), (-5.8, ±2.25), (-6.35, 0), (-6.35, ±1.5), (-6.35,

471  $\pm 3$ ), ( $-7, \pm 0.75$ ), and ( $-7, \pm 2.25$ ), with a series of depth (mm): 2, 1.5, 1, 0.5, and volume was  
472 0.3  $\mu\text{l}/\text{depth}$ . Viruses were coded during virus injection and remained blinded throughout  
473 the whole study until data analyses were done.

474

#### 475 **Quantitative RT-PCR**

476 Virus-infected cerebellar tissue indicated by tdTomato was carefully dissected under  
477 fluorescence microscope. RNA was extracted using Qiagen RNeasy Plus Mini Kit with the  
478 manufacturer's protocol (Qiagen, Hilden, Germany). Quantitative RT-PCR was run in  
479 QuantStudio 3 (Applied biosystems, Thermo Fisher Scientific, USA) using TaqMan Fast  
480 Virus 1-Step Master Mix (PN4453800, Applied biosystems, Thermo Fisher Scientific, USA).  
481 PrimerTime primers and FAM-dye coupled detection probes were used for detecting *Clstn3*  
482 mRNA level. To detect genome editing efficiency, qPCR primers and probe were targeting  
483 the two exons and designed to flank the double-strand breaks of the two sgRNAs (Yu et al.,  
484 2014). (*Clstn3*: Forward primer: AGAGTACCAGGGCATTGTCA; reverse primer:  
485 GATCACAGCCTCGAAGGGTA; probe: TGGATAAAGATGCTCCACTGCGCT). A  
486 commercially-available GAPDH probe was used as internal control (Cat: 4352932E,  
487 Applied Biosystems).

488

#### 489 **Immunohistochemistry**

490 Immunohistochemistry on the cerebellar cortex was done as previously reported (Zhang et  
491 al., 2015). Mice were anesthetized with isoflurane and sequentially perfused with  
492 phosphate buffered saline (PBS) and ice cold 4% paraformaldehyde (PFA). Brains were  
493 dissected and post-fixed in 4% PFA overnight, then cryoprotected in 30% sucrose in PBS  
494 for 24 h. 40  $\mu\text{m}$  thick sagittal sections of cerebellum were collected using a Leica  
495 CM3050-S cryostat (Leica, Germany). Free floating brain sections were incubated with  
496 blocking buffer (5% goat serum, 0.3% Triton X-100) for 1 h at room temperature, then  
497 treated with primary antibodies diluted in blocking buffer overnight at 4  $^{\circ}\text{C}$  (anti-vGluT1,  
498 Rabbit, YZ6089, Yenzym, 1:1,000; anti-vGluT2, Rabbit, YZ6097, 1:1,000, Yenzym;  
499 anti-vGAT, guinea pig, 131004, Sysy, 1:1,000). Sections were washed three times with PBS  
500 (15 min each), then treated with secondary antibodies (Alexa goat anti guinea pig 633,

501 A-21105, Invitrogen, 1:1,000; or Alexa goat anti rabbit 647, A-21245, Invitrogen, 1:1,000)  
502 for 2 h at room temperature. After washing with PBS 4 times (15 min each), sections were  
503 stained with DAPI (D8417, Sigma) and mounted onto Superfrost Plus slides with mounting  
504 media. Confocal images were acquired with a Nikon confocal microscope (A1Rsi, Nikon,  
505 Japan) with 60x oil objective, at 1024 x 1024 pixels, with z-stack distance of 0.3  $\mu$ m. All  
506 acquisition parameters were kept constant within the same day between control and *Clstn3*  
507 KO groups. Images were taken from cerebellar lobules IV/V. Images were analyzed with  
508 Nikon analysis software. During analysis, we divided the cerebellar cortex into different  
509 layers to compare *Clstn3* KO effects. We defined 0-40% as superficial molecular layer and  
510 40-80% as molecular deep layers, 80-100% as PCL, and we analyzed and labeled GCL  
511 separately in vGAT staining.

512

### 513 **Immunoblotting**

514 Immunoblotting was performed as described previously (Zhang et al., 2015). Mice were  
515 anesthetized with isoflurane and decapitated on ice, with the cerebellum dissected out and  
516 homogenized in RIPA buffer (in mM: 50 Tris-HCl pH7.4, 150 NaCl, 1% Triton X-100, 0.1%  
517 SDS, 1 EDTA) with protease inhibitor cocktail (5056489001, Millipore Sigma) and kept on  
518 ice for 30 min. Samples were centrifuged at 14,000 rpm for 20 min at 4  $^{\circ}$ C, supernatant  
519 were kept and stored in -80  $^{\circ}$ C until use. Proteins were loaded onto 4-20% MIDI Criterion  
520 TGX precast SDS-PAGE gels (5671094, Bio-Rad), and gels were blotted onto  
521 nitrocellulose membranes using the Trans-blot turbo transfer system (Bio-Rad).  
522 Membranes were blocked in 5% milk diluted in PBS for 1 h at room temperature, then  
523 incubated overnight at 4  $^{\circ}$ C with primary antibodies diluted in 5% milk in TBST (0.1%  
524 Tween-20). Primary antibodies of anti-*Clstn3* (Rabbit, 1:1,000) and anti-pan *Clstn1* and 2  
525 (Rabbit, 1:1,000) were previously described (Um et al., 2014). Antibody against beta-actin  
526 from Sigma (A1978, Mouse, 1:10,000) was used as a loading control.

527 Membranes were then washed with TBST and incubated with fluorescence labeled IRDye  
528 secondary antibodies (IRDye<sup>®</sup> 680LT Donkey anti-Rabbit, 926-68023, LI-COR, 1:10,000;  
529 IRDye<sup>®</sup> 800CW donkey anti-mouse, 926-68023, LI-COR, 1:10,000). Signals were detected

530 with Odyssey CLx imaging systems (LI-COR) and data were analyzed with Image Studio  
531 5.2 software. Total intensity values were normalized to actin prior to control.

532

### 533 **Electrophysiology**

534 Cerebellar electrophysiology was carried out as described previously (Caillard et al., 2000;  
535 Foster and Regehr, 2004; Llano et al., 1991; Zhang et al., 2015). Briefly, the cerebellum  
536 was rapidly removed and transferred into continuously oxygenated ice cold cutting  
537 solutions (in mM: 125 NaCl, 2.5 KCl, 3 MgCl<sub>2</sub>, 0.1 CaCl<sub>2</sub>, 25 glucose, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 0.4  
538 ascorbic acid, 3 myo-inositol, 2 Na-pyruvate, and 25 NaHCO<sub>3</sub>). 250 μm sagittal slices were  
539 cut using a vibratome (VT1200S, Leica, Germany) and recovered at room temperature for  
540 >1 h before recording. Oxygenated ACSF (in mM: 125 NaCl, 2.5 KCl, 1 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>, 25  
541 glucose, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 0.4 ascorbic acid, 3 myo-inositol, 2 Na-pyruvate, and 25 NaHCO<sub>3</sub>)  
542 was perfused at 1 ml/min during recording. Whole cell recordings with Purkinje cells were  
543 from cerebellar lobules IV/V, with patch pipettes (2-3 MΩ) pulled from borosilicate pipettes  
544 (TW150-4, WPI, USA) using PC-10 puller (Narishige, Japan). The following internal  
545 solutions were used (in mM): (1) for EPSC, 140 CsMeSO<sub>3</sub>, 8 CsCl, 10 HEPES, 0.25 EGTA,  
546 2 Mg-ATP, 0.2 Na-GTP (pH adjusted to 7.25 with CsOH); (2) for IPSC, 145 CsCl, 10  
547 HEPES, 2 MgCl<sub>2</sub>, 0.5 EGTA, 2 Mg-ATP, 0.2 Na-GTP (pH adjusted to 7.25 with CsOH).  
548 Liquid junction was not corrected during all recordings. For all EPSC recordings, 50 μM  
549 picrotoxin (1128, Tocris) and 10 μM APV (0106, Tocris) were contained in ACSF, and (1)  
550 additionally 0.5 μM NBQX (1044, Tocris) were included for climbing-fiber EPSC recordings;  
551 (2) 1 μM TTX (Tetrodotoxin, 14964, Cayman Chemical) for mEPSC recordings. For all  
552 IPSC recordings, (1) 10 μM CNQX (1045, Tocris) and 10 μM APV were included in ACSF,  
553 and (2) 1 μM TTX were included in mIPSC recordings. A glass theta electrode (64-0801,  
554 Warner Instruments, USA, pulled with PC-10) filled with ACSF was used as stimulating  
555 electrode, and littermate control and Clstn3 knockout mice were analyzed meanwhile using  
556 the same stimulating electrode. For climbing fibers, the electrode was placed in the granule  
557 cell layer around Purkinje cells and identified by all-or-none response, together with  
558 paired-pulse depression at 50 ms inter-stimulus interval (Eccles et al., 1966; Zhang et al.,  
559 2015). For parallel fibers, electrodes were placed in distal molecular layer with the same  
560 distance for both control and Clstn3 knockout mice (~200 μm from the recorded Purkinje

561 cell) and identified by paired-pulse facilitation at 50 ms inter-stimulus interval (Zhang et al.,  
562 2015). For basket cell stimulations, electrodes were placed in the proximal molecular layer  
563 (within~100  $\mu\text{m}$  from the recorded Purkinje cell) and also identified with all-or-none  
564 response (Caillard et al., 2000; Zhang et al., 2015). Cells with  $>20\%$  changes in series  
565 resistances were rejected for further analysis. All electrophysiological data were sampled  
566 with Digidata1440 (Molecular Device, USA) and analyzed with Clampfit10.4. Coefficient of  
567 variation was calculated according to previous report (Lisman et al., 2007).

568

### 569 **Biocytin labeling in Purkinje cells**

570 2 mg/ml Biocytin (B4261, Sigma) was dissolved in Cs-methanesulfonate internal solution  
571 followed by whole-cell voltage clamp recordings in the Purkinje cells (Sando et al., 2019).  
572 Slices were fixed in 4% PFA/PBS solution overnight at 4°C. Slices were then washed 3 X 5  
573 mins with PBS, permeabilized, and blocked in 5% goat serum, 0.5% Triton-X100 in PBS at  
574 room temperature for 1 h. Then slices were incubated in 1:1,000 diluted Streptavidin  
575 Fluor™ 647 conjugate (S21374, Invitrogen) at room temperature for 2 h in 5% goat serum  
576 in PBS, washed 5 X 5 min with PBS, and mounted onto Superfrost Plus slides for imaging.  
577 Image overviews were obtained with a Nikon confocal microscope (A1Rsi, Nikon, Japan)  
578 with a 60x oil objective, at 1024 x 1024 pixels, with z-stack distance of 2  $\mu\text{m}$ . Dendritic tree  
579 3D reconstructions were performed using Neurolucida360 software (MBF science, USA) in  
580 the Stanford Neuroscience Microscopy Service Center. Note that some somas could not be  
581 detected automatically and were manually labeled. Spine images were obtained with a  
582 ZEISS LSM980 inverted confocal, Airyscan2 for fast super-resolution setup, equipped with  
583 an oil-immersion 63X objective. Z-stacks were collected at 0.2  $\mu\text{m}$  intervals at 0.06  $\mu\text{m}/\text{pixel}$   
584 resolution with Airyscan2. Spine images were deconvolved using ZEN blue software  
585 (ZEISS). Spine density and characteristics were analyzed with Neurolucida360 software  
586 (MBF science, USA) in Stanford Neuroscience Microscopy Service Center. Only last order  
587 dendrites were analyzed, with 5-8 dendrites per cell per layer.

588

### 589 **Behavior**

590 *Accelerating rotarod.* Mice were placed on an accelerating rotarod (IITC Life Science). The  
591 rod accelerated from 4 to 40 r.p.m. in 5 min. Mice were tested 3 times per day with 1 hour  
592 interval and repeated for 3 days. Time stayed on the rod was recorded while the mouse fell  
593 off, or hanged on without climbing, or reached 5 min.

594 *Three-chamber social interaction.* Social interaction was evaluated in a three-chamber box.  
595 Mice were placed initially in the central chamber to allow 10 min habituation for all three  
596 chambers. For sociability session, a same sex- and age matched stranger mouse  
597 (stranger1) was placed inside an upside-down wire pencil cup in one of the side chambers.  
598 The other side had the same empty pencil cup. A test mouse was allowed 10 min to  
599 investigate the three chambers. For social novelty session, another stranger mouse  
600 (stranger2) was placed into the empty pencil cup and test mouse was allowed another 10  
601 min to investigate between three chambers. The time mice spent in each chamber was  
602 recorded and analyzed using BIOBSERVE III tracking system.

603

## 604 **Data analysis**

605 Experiments and data analyses were performed blindly by coding viruses. Unpaired t-test  
606 or one-way ANOVA or two-way ANOVA or repeat measures ANOVA were used to analyze  
607 slice physiology data or immunohistochemistry data or behavior data as indicated in figure  
608 legends. Kolmogorov-Smirnov test was used to analyze the cumulative curves of mEPSCs  
609 or mIPSCs. Significance was indicated as \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . Data are  
610 expressed as means  $\pm$  SEM.

611

## 612 **AUTHOR CONTRIBUTIONS**

613 Z.L. performed AAV preparation, stereotactic injections, qRT-PCR, immunoblotting,  
614 immunohistochemistry, biocytin morphological study, cerebellar electrophysiology and  
615 behavior; M.J. designed sgRNAs, made the sgRNA vector and tested sgRNAs genome  
616 editing efficiency; K.L.A. performed in-situ hybridization; J.K. provided antibodies against  
617 Clstn1/2 and Clstn3, and R.S.Z. performed additional electrophysiological recordings. Z.L.,  
618 M.J., and K.L.A. analyzed the data. Z.L. and T.C.S. wrote the manuscript.

619



620 **ACKNOWLEDGEMENTS**

621 We thank Drs Bo Zhang, Justin Howard Trotter, Karthik Raju, Mu Zhou, and Richard Sando  
622 for advice, discussions, and help in this project. This paper was supported by a grant from  
623 NIH (MH052804 to T.C.S.).

624

625 **CONFLICT OF INTEREST**

626 The authors declare no conflict of interest.

627 **REFERENCE**

628

- 629 Anderson, G.R., S. Maxeiner, R. Sando, T. Tsetsenis, R.C. Malenka, and T.C. Sudhof.  
630 2017. Postsynaptic adhesion GPCR latrophilin-2 mediates target recognition in  
631 entorhinal-hippocampal synapse assembly. *J Cell Biol.* 216:3831-3846. DOI:  
632 10.1083/jcb.201703042, PMCID: 5674891
- 633 Araki, Y., T. Kawano, H. Taru, Y. Saito, S. Wada, K. Miyamoto, H. Kobayashi, H.O.  
634 Ishikawa, Y. Ohsugi, T. Yamamoto, K. Matsuno, M. Kinjo, and T. Suzuki. 2007. The  
635 novel cargo Alcadein induces vesicle association of kinesin-1 motor components  
636 and activates axonal transport. *EMBO J.* 26:1475-1486. DOI:  
637 10.1038/sj.emboj.7601609, PMCID: 1829376
- 638 Araki, Y., S. Tomita, H. Yamaguchi, N. Miyagi, A. Sumioka, Y. Kirino, and T. Suzuki. 2003.  
639 Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like  
640 protein-mediated stabilization of amyloid beta-protein precursor metabolism. *J Biol*  
641 *Chem.* 278:49448-49458. DOI: 10.1074/jbc.M306024200, PMCID:
- 642 Attardo, A., J.E. Fitzgerald, and M.J. Schnitzer. 2015. Impermanence of dendritic spines in  
643 live adult CA1 hippocampus. *Nature.* 523:592-596. DOI: 10.1038/nature14467,  
644 PMCID: 4648621
- 645 Baude, A., E. Molnar, D. Latawiec, R.A. McIlhinney, and P. Somogyi. 1994. Synaptic and  
646 nonsynaptic localization of the GluR1 subunit of the AMPA-type excitatory amino  
647 acid receptor in the rat cerebellum. *J Neurosci.* 14:2830-2843. DOI: PMCID:  
648 6577479
- 649 Bolliger, M.F., D.C. Martinelli, and T.C. Sudhof. 2011. The cell-adhesion G protein-coupled  
650 receptor BAI3 is a high-affinity receptor for C1q-like proteins. *Proc Natl Acad Sci U S*  
651 *A.* 108:2534-2539. DOI: 10.1073/pnas.1019577108, PMCID: 3038708
- 652 Briatore, F., G. Pregno, S. Di Angelantonio, E. Frola, M.E. De Stefano, C. Vaillend, M.  
653 Sasso-Pognetto, and A. Patrizi. 2020. Dystroglycan Mediates Clustering of  
654 Essential GABAergic Components in Cerebellar Purkinje Cells. *Front Mol Neurosci.*  
655 13:164. DOI: 10.3389/fnmol.2020.00164, PMCID: 7485281
- 656 Brinkman, E.K., T. Chen, M. Amendola, and B. van Steensel. 2014. Easy quantitative  
657 assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res.*  
658 42:e168. DOI: 10.1093/nar/gku936, PMCID: 4267669
- 659 Caillard, O., H. Moreno, B. Schwaller, I. Llano, M.R. Celio, and A. Marty. 2000. Role of the  
660 calcium-binding protein parvalbumin in short-term synaptic plasticity. *Proc Natl Acad*  
661 *Sci U S A.* 97:13372-13377. DOI: 10.1073/pnas.230362997, PMCID: 27231
- 662 Cesa, R., and P. Strata. 2009. Axonal competition in the synaptic wiring of the cerebellar  
663 cortex during development and in the mature cerebellum. *Neuroscience.*  
664 162:624-632. DOI: 10.1016/j.neuroscience.2009.02.061, PMCID:
- 665 Chanda, S., W.D. Hale, B. Zhang, M. Wernig, and T.C. Sudhof. 2017. Unique versus  
666 Redundant Functions of Neuroligin Genes in Shaping Excitatory and Inhibitory

667 Synapse Properties. *J Neurosci.* 37:6816-6836. DOI:  
668 10.1523/JNEUROSCI.0125-17.2017, PMCID: 5518416

669 Chen, L.Y., M. Jiang, B. Zhang, O. Gokce, and T.C. Sudhof. 2017. Conditional Deletion of  
670 All Neurexins Defines Diversity of Essential Synaptic Organizer Functions for  
671 Neurexins. *Neuron.* 94:611-625 e614. DOI: 10.1016/j.neuron.2017.04.011, PMCID:  
672 5501922

673 Dickinson, M.E., A.M. Flenniken, X. Ji, L. Teboul, M.D. Wong, J.K. White, T.F. Meehan, W.J.  
674 Weninger, H. Westerberg, H. Adissu, C.N. Baker, L. Bower, J.M. Brown, L.B. Caddle,  
675 F. Chiani, D. Clary, J. Cleak, M.J. Daly, J.M. Denegre, B. Doe, M.E. Dolan, S.M.  
676 Edie, H. Fuchs, V. Gailus-Durner, A. Galli, A. Gambadoro, J. Gallegos, S. Guo, N.R.  
677 Horner, C.W. Hsu, S.J. Johnson, S. Kalaga, L.C. Keith, L. Lanoue, T.N. Lawson, M.  
678 Lek, M. Mark, S. Marschall, J. Mason, M.L. McElwee, S. Newbigging, L.M. Nutter,  
679 K.A. Peterson, R. Ramirez-Solis, D.J. Rowland, E. Ryder, K.E. Samocha, J.R.  
680 Seavitt, M. Selloum, Z. Szoke-Kovacs, M. Tamura, A.G. Trainor, I. Tudose, S.  
681 Wakana, J. Warren, O. Wendling, D.B. West, L. Wong, A. Yoshiki, C. International  
682 Mouse Phenotyping, L. Jackson, I.C.d.I.S. Infrastructure Nationale Phenomin, L.  
683 Charles River, M.R.C. Harwell, P. Toronto Centre for, I. Wellcome Trust Sanger, R.B.  
684 Center, D.G. MacArthur, G.P. Tocchini-Valentini, X. Gao, P. Flicek, A. Bradley, W.C.  
685 Skarnes, M.J. Justice, H.E. Parkinson, M. Moore, S. Wells, R.E. Braun, K.L.  
686 Svenson, M.H. de Angelis, Y. Herault, T. Mohun, A.M. Mallon, R.M. Henkelman, S.D.  
687 Brown, D.J. Adams, K.C. Lloyd, C. McKerlie, A.L. Beaudet, M. Bucan, and S.A.  
688 Murray. 2016. High-throughput discovery of novel developmental phenotypes.  
689 *Nature.* 537:508-514. DOI: 10.1038/nature19356, PMCID: 5295821

690 Dinamarca, M.C., A. Raveh, A. Schneider, T. Fritzius, S. Fruh, P.D. Rem, M. Stawarski, T.  
691 Lalanne, R. Turecek, M. Choo, V. Besseyrias, W. Bildl, D. Bentrop, M. Staufienbiel,  
692 M. Gassmann, B. Fakler, J. Schwenk, and B. Bettler. 2019. Complex formation of  
693 APP with GABAB receptors links axonal trafficking to amyloidogenic processing. *Nat*  
694 *Commun.* 10:1331. DOI: 10.1038/s41467-019-09164-3, PMCID: 6430795

695 Eccles, J.C., R. Llinas, and K. Sasaki. 1966. The excitatory synaptic action of climbing  
696 fibres on the Purkinje cells of the cerebellum. *J Physiol.* 182:268-296. DOI:  
697 10.1113/jphysiol.1966.sp007824, PMCID: 1357472

698 Emperador-Melero, J., G. de Nola, and P.S. Kaeser. 2021. Intact synapse structure and  
699 function after combined knockout of PTPdelta, PTPsigma, and LAR. *Elife.* 10. DOI:  
700 10.7554/eLife.66638, PMCID: 7963474

701 Foster, K.A., and W.G. Regehr. 2004. Variance-mean analysis in the presence of a rapid  
702 antagonist indicates vesicle depletion underlies depression at the climbing fiber  
703 synapse. *Neuron.* 43:119-131. DOI: 10.1016/j.neuron.2004.06.022, PMCID:  
704 Fritschy, J.M., P. Panzanelli, J.E. Kralic, K.E. Vogt, and M. Sassoe-Pognetto. 2006.  
705 Differential dependence of axo-dendritic and axo-somatic GABAergic synapses on  
706 GABAA receptors containing the alpha1 subunit in Purkinje cells. *J Neurosci.*  
707 26:3245-3255. DOI: 10.1523/JNEUROSCI.5118-05.2006, PMCID: 6674111

708 Fukai, S., and T. Yoshida. 2020. Roles of type IIa receptor protein tyrosine phosphatases  
709 as synaptic organizers. *FEBS J.* DOI: 10.1111/febs.15666, PMID:

710 Gotoh, N., Y. Saito, S. Hata, H. Saito, D. Ojima, C. Murayama, M. Shigeta, T. Abe, D.  
711 Konno, F. Matsuzaki, T. Suzuki, and T. Yamamoto. 2020. Amyloidogenic processing  
712 of amyloid beta protein precursor (APP) is enhanced in the brains of alcadein  
713 alpha-deficient mice. *J Biol Chem.* 295:9650-9662. DOI: 10.1074/jbc.RA119.012386,  
714 PMID: 7363152

715 Grimm, D., J.S. Lee, L. Wang, T. Desai, B. Akache, T.A. Storm, and M.A. Kay. 2008. In  
716 vitro and in vivo gene therapy vector evolution via multispecies interbreeding and  
717 retargeting of adeno-associated viruses. *J Virol.* 82:5887-5911. DOI:  
718 10.1128/JVI.00254-08, PMID: 2395137

719 Hintsch, G., A. Zurlinden, V. Meskenaite, M. Steuble, K. Fink-Widmer, J. Kinter, and P.  
720 Sonderegger. 2002. The calyntenins--a family of postsynaptic membrane proteins  
721 with distinct neuronal expression patterns. *Mol Cell Neurosci.* 21:393-409. DOI:  
722 10.1006/mcne.2002.1181, PMID:

723 Hioki, H., F. Fujiyama, K. Taki, R. Tomioka, T. Furuta, N. Tamamaki, and T. Kaneko. 2003.  
724 Differential distribution of vesicular glutamate transporters in the rat cerebellar cortex.  
725 *Neuroscience.* 117:1-6. DOI: 10.1016/s0306-4522(02)00943-0, PMID:

726 Incontro, S., C.S. Asensio, R.H. Edwards, and R.A. Nicoll. 2014. Efficient, complete  
727 deletion of synaptic proteins using CRISPR. *Neuron.* 83:1051-1057. DOI:  
728 10.1016/j.neuron.2014.07.043, PMID: 4195490

729 Kakegawa, W., N. Mitakidis, E. Miura, M. Abe, K. Matsuda, Y.H. Takeo, K. Kohda, J.  
730 Motohashi, A. Takahashi, S. Nagao, S. Muramatsu, M. Watanabe, K. Sakimura, A.R.  
731 Aricescu, and M. Yuzaki. 2015. Anterograde C1q1 signaling is required in order to  
732 determine and maintain a single-winner climbing fiber in the mouse cerebellum.  
733 *Neuron.* 85:316-329. DOI: 10.1016/j.neuron.2014.12.020, PMID:

734 Kim, H., D. Kim, J. Kim, H.Y. Lee, D. Park, H. Kang, K. Matsuda, F.H. Sterky, M. Yuzaki,  
735 J.Y. Kim, S.Y. Choi, J. Ko, and J.W. Um. 2020. Calyntenin-3 interacts with both  
736 alpha- and beta-neurexins in the regulation of excitatory synaptic innervation in  
737 specific Schaffer collateral pathways. *J Biol Chem.* 295:9244-9262. DOI:  
738 10.1074/jbc.RA120.013077, PMID: 7335786

739 Ko, J., C. Zhang, D. Arac, A.A. Boucard, A.T. Brunger, and T.C. Sudhof. 2009. Neuroligin-1  
740 performs neurexin-dependent and neurexin-independent functions in synapse  
741 validation. *EMBO J.* 28:3244-3255. DOI: 10.1038/emboj.2009.249, PMID:  
742 2771087

743 Konecna, A., R. Frischknecht, J. Kinter, A. Ludwig, M. Steuble, V. Meskenaite, M.  
744 Indermuhle, M. Engel, C. Cen, J.M. Mateos, P. Streit, and P. Sonderegger. 2006.  
745 Calyntenin-1 docks vesicular cargo to kinesin-1. *Mol Biol Cell.* 17:3651-3663. DOI:  
746 10.1091/mbc.e06-02-0112, PMID: 1525238

747 Lipina, T.V., T. Prasad, D. Yokomaku, L. Luo, S.A. Connor, H. Kawabe, Y.T. Wang, N.  
748 Brose, J.C. Roder, and A.M. Craig. 2016. Cognitive Deficits in

749 Calsyntenin-2-deficient Mice Associated with Reduced GABAergic Transmission.  
750 *Neuropsychopharmacology*. 41:802-810. DOI: 10.1038/npp.2015.206, PMCID:  
751 4707826

752 Lisman, J.E., S. Raghavachari, and R.W. Tsien. 2007. The sequence of events that  
753 underlie quantal transmission at central glutamatergic synapses. *Nat Rev Neurosci*.  
754 8:597-609. DOI: 10.1038/nrn2191, PMCID:  
755 Llano, I., A. Marty, C.M. Armstrong, and A. Konnerth. 1991. Synaptic- and agonist-induced  
756 excitatory currents of Purkinje cells in rat cerebellar slices. *J Physiol*. 434:183-213.  
757 DOI: 10.1113/jphysiol.1991.sp018465, PMCID: 1181413

758 Ludwig, A., J. Blume, T.M. Diep, J. Yuan, J.M. Mateos, K. Leuthauser, M. Steuble, P. Streit,  
759 and P. Sonderegger. 2009. Calsyntenins mediate TGN exit of APP in a  
760 kinesin-1-dependent manner. *Traffic*. 10:572-589. DOI:  
761 10.1111/j.1600-0854.2009.00886.x, PMCID:  
762 Meng, X., C.M. McGraw, W. Wang, J. Jing, S.Y. Yeh, L. Wang, J. Lopez, A.M. Brown, T.  
763 Lin, W. Chen, M. Xue, R.V. Sillitoe, X. Jiang, and H.Y. Zoghbi. 2019. Neurexophilin4  
764 is a selectively expressed alpha-neurexin ligand that modulates specific cerebellar  
765 synapses and motor functions. *Elife*. 8. DOI: 10.7554/eLife.46773, PMCID: 6763262

766 Missler, M., W. Zhang, A. Rohlmann, G. Kattenstroth, R.E. Hammer, K. Gottmann, and T.C.  
767 Sudhof. 2003. Alpha-neurexins couple Ca<sup>2+</sup> channels to synaptic vesicle exocytosis.  
768 *Nature*. 423:939-948. DOI: 10.1038/nature01755, PMCID:  
769 Miyazaki, T., M. Yamasaki, K. Hashimoto, M. Yamazaki, M. Abe, H. Usui, M. Kano, K.  
770 Sakimura, and M. Watanabe. 2012. Cav2.1 in cerebellar Purkinje cells regulates  
771 competitive excitatory synaptic wiring, cell survival, and cerebellar biochemical  
772 compartmentalization. *J Neurosci*. 32:1311-1328. DOI:  
773 10.1523/JNEUROSCI.2755-11.2012, PMCID: 6796260

774 Monday, H.R., T.J. Younts, and P.E. Castillo. 2018. Long-Term Plasticity of  
775 Neurotransmitter Release: Emerging Mechanisms and Contributions to Brain  
776 Function and Disease. *Annu Rev Neurosci*. 41:299-322. DOI:  
777 10.1146/annurev-neuro-080317-062155, PMCID: 6238218

778 Nakayama, H., T. Miyazaki, K. Kitamura, K. Hashimoto, Y. Yanagawa, K. Obata, K.  
779 Sakimura, M. Watanabe, and M. Kano. 2012. GABAergic inhibition regulates  
780 developmental synapse elimination in the cerebellum. *Neuron*. 74:384-396. DOI:  
781 10.1016/j.neuron.2012.02.032, PMCID:  
782 Nelson, S.B., and V. Valakh. 2015. Excitatory/Inhibitory Balance and Circuit Homeostasis in  
783 Autism Spectrum Disorders. *Neuron*. 87:684-698. DOI:  
784 10.1016/j.neuron.2015.07.033, PMCID: 4567857

785 Ohno, H., S. Kato, Y. Naito, H. Kunitomo, M. Tomioka, and Y. Iino. 2014. Role of synaptic  
786 phosphatidylinositol 3-kinase in a behavioral learning response in *C. elegans*.  
787 *Science*. 345:313-317. DOI: 10.1126/science.1250709, PMCID:  
788 Peng, J., A.L. Sheng, Q. Xiao, L. Shen, X.C. Ju, M. Zhang, S.T. He, C. Wu, and Z.G. Luo.  
789 2019. Single-cell transcriptomes reveal molecular specializations of neuronal cell

790 types in the developing cerebellum. *J Mol Cell Biol.* 11:636-648. DOI:  
791 10.1093/jmcb/mjy089, PMID: 6788728

792 Pettem, K.L., D. Yokomaku, L. Luo, M.W. Linhoff, T. Prasad, S.A. Connor, T.J. Siddiqui, H.  
793 Kawabe, F. Chen, L. Zhang, G. Rudenko, Y.T. Wang, N. Brose, and A.M. Craig.  
794 2013. The specific alpha-neurexin interactor calsyntenin-3 promotes excitatory and  
795 inhibitory synapse development. *Neuron.* 80:113-128. DOI:  
796 10.1016/j.neuron.2013.07.016, PMID: 3821696

797 Pfeiffer, T., S. Poll, S. Bancelin, J. Angibaud, V.K. Inavalli, K. Keppler, M. Mittag, M.  
798 Fuhrmann, and U.V. Nagerl. 2018. Chronic 2P-STED imaging reveals high turnover  
799 of dendritic spines in the hippocampus in vivo. *Elife.* 7. DOI: 10.7554/eLife.34700,  
800 PMID: 6014725

801 Platt, R.J., S. Chen, Y. Zhou, M.J. Yim, L. Swiech, H.R. Kempton, J.E. Dahlman, O. Parnas,  
802 T.M. Eisenhaure, M. Jovanovic, D.B. Graham, S. Jhunjunwala, M. Heidenreich, R.J.  
803 Xavier, R. Langer, D.G. Anderson, N. Hacohen, A. Regev, G. Feng, P.A. Sharp, and  
804 F. Zhang. 2014. CRISPR-Cas9 knockin mice for genome editing and cancer  
805 modeling. *Cell.* 159:440-455. DOI: 10.1016/j.cell.2014.09.014, PMID: 4265475

806 Ranneva, S.V., V.F. Maksimov, I.M. Korostyshevskaja, and T.V. Lipina. 2020. Lack of  
807 synaptic protein, calsyntenin-2, impairs morphology of synaptic complexes in mice.  
808 *Synapse.* 74:e22132. DOI: 10.1002/syn.22132, PMID:  
809 Südhof, T.C. 2021. The Cell Biology of Synapse Formation. *Journal of Cell Biology.* in press.  
810 DOI: PMID:

811 Sando, R., X. Jiang, and T.C. Südhof. 2019. Latrophilin GPCRs direct synapse specificity  
812 by coincident binding of FLRTs and teneurins. *Science.* 363. DOI:  
813 10.1126/science.aav7969, PMID: 6636343

814 Sando, R., and T.C. Südhof. 2021. Latrophilin GPCR signaling mediates synapse formation.  
815 *Elife.* 10. DOI: 10.7554/eLife.65717, PMID: 7954527

816 Saunders, A., E.Z. Macosko, A. Wysoker, M. Goldman, F.M. Krienen, H. de Rivera, E. Bien,  
817 M. Baum, L. Bortolin, S. Wang, A. Goeva, J. Nemes, N. Kamitaki, S. Brumbaugh, D.  
818 Kulp, and S.A. McCarroll. 2018. Molecular Diversity and Specializations among the  
819 Cells of the Adult Mouse Brain. *Cell.* 174:1015-1030 e1016. DOI:  
820 10.1016/j.cell.2018.07.028, PMID: 6447408


821 Schaum, N., J. Karkanias, N.F. Neff, A.P. May, S.R. Quake, T. Wyss-Coray, S. Darmanis, J.  
822 Batson, O. Botvinnik, M.B. Chen, S. Chen, F. Green, R.C. Jones, A. Maynard, L.  
823 Penland, A.O. Pisco, R.V. Sit, G.M. Stanley, J.T. Webber, F. Zanini, A.S. Baghel, I.  
824 Bakerman, I. Bansal, D. Berdnik, B. Bilen, D. Brownfield, C. Cain, M.B. Chen, S.  
825 Chen, M. Cho, G. Cirolia, S.D. Conley, S. Darmanis, A. Demers, K. Demir, A. de  
826 Morree, T. Divita, H. du Bois, L.B.T. Dulgeroff, H. Ebadi, F.H. Espinoza, M. Fish, Q.  
827 Gan, B.M. George, A. Gillich, F. Green, G. Genetiano, X. Gu, G.S. Gulati, Y. Hang, S.  
828 Hosseinzadeh, A. Huang, T. Iram, T. Isobe, F. Ives, R.C. Jones, K.S. Kao, G.  
829 Karnam, A.M. Kershner, B.M. Kiss, W. Kong, M.E. Kumar, J.Y. Lam, D.P. Lee, S.E.  
830 Lee, G. Li, Q. Li, L. Liu, A. Lo, W.-J. Lu, A. Manjunath, A.P. May, K.L. May, O.L. May,

831 A. Maynard, M. McKay, R.J. Metzger, M. Mignardi, D. Min, A.N. Nabhan, N.F. Neff,  
832 K.M. Ng, J. Noh, R. Patkar, W.C. Peng, L. Penland, R. Puccinelli, E.J. Rulifson, N.  
833 Schaum, S.S. Sikandar, R. Sinha, R.V. Sit, K. Szade, W. Tan, C. Tato, K. Tellez, K.J.  
834 Travaglini, C. Tropini, L. Waldburger, L.J. van Weele, et al. 2018. Single-cell  
835 transcriptomics of 20 mouse organs creates a Tabula Muris. *Nature*. 562:367-372.  
836 DOI: 10.1038/s41586-018-0590-4, PMCID:  
837 Schwenk, J., E. Perez-Garci, A. Schneider, A. Kollwe, A. Gauthier-Kemper, T. Fritzius, A.  
838 Raveh, M.C. Dinamarca, A. Hanuschkin, W. Bildl, J. Klingauf, M. Gassmann, U.  
839 Schulte, B. Bettler, and B. Fakler. 2016. Modular composition and dynamics of  
840 native GABAB receptors identified by high-resolution proteomics. *Nat Neurosci*.  
841 19:233-242. DOI: 10.1038/nn.4198, PMCID:  
842 Sclip, A., and T.C. Sudhof. 2020. LAR receptor phospho-tyrosine phosphatases regulate  
843 NMDA-receptor responses. *Elife*. 9. DOI: 10.7554/eLife.53406, PMCID: 6984820  
844 Sigoillot, S.M., K. Iyer, F. Binda, I. Gonzalez-Calvo, M. Talleur, G. Vodjdani, P. Isope, and F.  
845 Selimi. 2015. The Secreted Protein C1QL1 and Its Receptor BAI3 Control the  
846 Synaptic Connectivity of Excitatory Inputs Converging on Cerebellar Purkinje Cells.  
847 *Cell Rep*. 10:820-832. DOI: 10.1016/j.celrep.2015.01.034, PMCID:  
848 Sotelo, C. 1975. Anatomical, physiological and biochemical studies of the cerebellum from  
849 mutant mice. II. Morphological study of cerebellar cortical neurons and circuits in the  
850 weaver mouse. *Brain Res*. 94:19-44. DOI: 10.1016/0006-8993(75)90874-4, PMCID:  
851 Ster, J., M. Steuble, C. Orlando, T.M. Diep, A. Akhmedov, O. Raineteau, V. Pernet, P.  
852 Sonderegger, and U. Gerber. 2014. Calsyntenin-1 regulates targeting of dendritic  
853 NMDA receptors and dendritic spine maturation in CA1 hippocampal pyramidal cells  
854 during postnatal development. *J Neurosci*. 34:8716-8727. DOI:  
855 10.1523/JNEUROSCI.0144-14.2014, PMCID: 6608200  
856 Strata, P., F. Tempia, M. Zagrebelsky, and F. Rossi. 1997. Reciprocal trophic interactions  
857 between climbing fibres and Purkinje cells in the rat cerebellum. *Prog Brain Res*.  
858 114:263-282. DOI: 10.1016/s0079-6123(08)63369-5, PMCID:  
859 Tasic, B., Z. Yao, L.T. Graybuck, K.A. Smith, T.N. Nguyen, D. Bertagnolli, J. Goldy, E.  
860 Garren, M.N. Economo, S. Viswanathan, O. Penn, T. Bakken, V. Menon, J. Miller, O.  
861 Fong, K.E. Hirokawa, K. Lathia, C. Rimorin, M. Tieu, R. Larsen, T. Casper, E.  
862 Barkan, M. Kroll, S. Parry, N.V. Shapovalova, D. Hirschstein, J. Pendergraft, H.A.  
863 Sullivan, T.K. Kim, A. Szafer, N. Dee, P. Groblewski, I. Wickersham, A. Cetin, J.A.  
864 Harris, B.P. Levi, S.M. Sunkin, L. Madisen, T.L. Daigle, L. Looger, A. Bernard, J.  
865 Phillips, E. Lein, M. Hawrylycz, K. Svoboda, A.R. Jones, C. Koch, and H. Zeng. 2018.  
866 Shared and distinct transcriptomic cell types across neocortical areas. *Nature*.  
867 563:72-78. DOI: 10.1038/s41586-018-0654-5, PMCID: 6456269  
868 Vagnoni, A., M.S. Perkinson, E.H. Gray, P.T. Francis, W. Noble, and C.C. Miller. 2012.  
869 Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and  
870 regulates Abeta production. *Hum Mol Genet*. 21:2845-2854. DOI:  
871 10.1093/hmg/dds109, PMCID: 3373235

872 Vogt, L., S.P. Schrimpf, V. Meskenaite, R. Frischknecht, J. Kinter, D.P. Leone, U. Ziegler,  
873 and P. Sonderegger. 2001. Calsyntenin-1, a proteolytically processed postsynaptic  
874 membrane protein with a cytoplasmic calcium-binding domain. *Mol Cell Neurosci.*  
875 17:151-166. DOI: 10.1006/mcne.2000.0937, PMID:  
876 Wang, C.Y., Z. Liu, Y.H. Ng, and T.C. Sudhof. 2020. A Synaptic Circuit Required for  
877 Acquisition but Not Recall of Social Transmission of Food Preference. *Neuron.*  
878 107:144-157 e144. DOI: 10.1016/j.neuron.2020.04.004, PMID: 7351611  
879 Wu, X., W.K. Morishita, A.M. Riley, W.D. Hale, T.C. Sudhof, and R.C. Malenka. 2019.  
880 Neuroligin-1 Signaling Controls LTP and NMDA Receptors by Distinct Molecular  
881 Pathways. *Neuron.* 102:621-635 e623. DOI: 10.1016/j.neuron.2019.02.013, PMID:  
882 6509009  
883 Yamasaki, M., K. Hashimoto, and M. Kano. 2006. Miniature synaptic events elicited by  
884 presynaptic Ca<sup>2+</sup> rise are selectively suppressed by cannabinoid receptor activation  
885 in cerebellar Purkinje cells. *J Neurosci.* 26:86-95. DOI:  
886 10.1523/JNEUROSCI.2258-05.2006, PMID: 6674295  
887 Yuzaki, M., and A.R. Aricescu. 2017. A GluD Coming-Of-Age Story. *Trends Neurosci.*  
888 40:138-150. DOI: 10.1016/j.tins.2016.12.004, PMID: 5553105  
889 Zeisel, A., H. Hochgerner, P. Lonnerberg, A. Johnsson, F. Memic, J. van der Zwan, M.  
890 Haring, E. Braun, L.E. Borm, G. La Manno, S. Codeluppi, A. Furlan, K. Lee, N.  
891 Skene, K.D. Harris, J. Hjerling-Leffler, E. Arenas, P. Ernfors, U. Marklund, and S.  
892 Linnarsson. 2018. Molecular Architecture of the Mouse Nervous System. *Cell.*  
893 174:999-1014 e1022. DOI: 10.1016/j.cell.2018.06.021, PMID: 6086934  
894 Zeng, X., M. Ye, J.M. Resch, M.P. Jedrychowski, B. Hu, B.B. Lowell, D.D. Ginty, and B.M.  
895 Spiegelman. 2019. Innervation of thermogenic adipose tissue via a calsyntenin  
896 3beta-S100b axis. *Nature.* 569:229-235. DOI: 10.1038/s41586-019-1156-9, PMID:  
897 6589139  
898 Zhang, B., L.Y. Chen, X. Liu, S. Maxeiner, S.J. Lee, O. Gokce, and T.C. Sudhof. 2015.  
899 Neuroligins Sculpt Cerebellar Purkinje-Cell Circuits by Differential Control of Distinct  
900 Classes of Synapses. *Neuron.* 87:781-796. DOI: 10.1016/j.neuron.2015.07.020,  
901 PMID: 4545494  
902 Zhou, M., M.D. Melin, W. Xu, and T.C. Sudhof. 2020. Dysfunction of parvalbumin neurons  
903 in the cerebellar nuclei produces an action tremor. *J Clin Invest.* 130:5142-5156. DOI:  
904 10.1172/JCI135802, PMID: 7524475



905 **FIGURES and FIGURE LEGENDS**




906  
 907 **Figure 1: *Clstn1*, *Clstn2*, and *Clstn3* expression targets overlapping neuronal**  
 908 **populations in the dorsal hippocampus, but distinct neuronal populations in the**  
 909 **cerebellum of mice**  
 910 **(A)** *Clstn1* (green), *Clstn2* (red) and *Clstn3* (magenta) exhibit distinct but largely  
 911 overlapping expression patterns in the dorsal hippocampus. Representative images show  
 912 sections from a mouse at P30 labeled by single-molecule *in situ* fluorescent hybridization

913 (RNAscope) and by DAPI staining as indicated (DG, dentate gyrus; CA1 and CA3, CA1-  
914 and CA3-regions of the hippocampus proper; mHb, medial habenula).

915 **(B & C)** *Clstn1* (green), *Clstn2* (red) and *Clstn3* (magenta) are expressed in separate and  
916 largely non-overlapping patterns in the cerebellum as visualized by single-molecule *in situ*  
917 hybridization (B, overview; C, expanded views of the area boxed in B; Mb, midbrain; ML,  
918 molecular layer; PCL, Purkinje cell layer; GCL, granule cell layer). Scale bars apply to all  
919 images in a set.

920



921

922 **Figure 2: CRISPR/Cas9 manipulations enable rapid and highly efficient *in vivo***  
 923 **deletions of *Clstn3* in Purkinje cells, resulting in a severe impairment in motor**  
 924 **learning**

925 **(A)** Schematic of the sgRNA design strategy. Both sgRNAs target the positive strand of  
 926 DNA, with sg66 targeting exon2, and sg21 targeting exon3.

927 **(B)** Schematic of the AAV-DJ expression cassette in which sgRNAs and tdTomato (tdT)  
 928 synthesis are driven by U6 and CAG promoters, respectively. Control mice were infected  
 929 with AAVs that lacked sgRNAs but were otherwise identical.

930 **(C)** Experimental strategy for CRISPR-mediated acute *Clstn3* deletions in the cerebellum.  
 931 AAVs expressing the sgRNAs and tdTomato were stereotactically injected into the

932 cerebellum of constitutively expressing Cas9 mice at P21, and mice were analyzed after  
933 P50.


934 **(D)** Quantitative RT-PCR shows that the CRISPR-mediated *Clstn3* deletion severely  
935 suppresses *Clstn3* mRNA levels in the total cerebellum. Relative gene expression levels  
936 were first normalized to GAPDH using threshold cycle (CT) values, and then normalized to  
937 control.

938 **(E)** Representative images of a cerebellar section from a mouse that was stereotactically  
939 infected with AAVs as described in **C** (left, overview of the cerebellum; right, cerebellar  
940 cortex; red = AAV-encoded tdTomato; blue, DAPI). Note that AAVs infect all Purkinje cells  
941 but few granule cells.

942 **(F)** Immunoblotting analyses confirm that the CRISPR-mediated deletion greatly  
943 suppresses *Clstn3* protein levels (left, representative immunoblot; right, summary graph of  
944 quantifications using fluorescently labeled secondary antibodies).

945 **(G)** The CRISPR-mediated *Clstn3* KO in cerebellar Purkinje cells severely impairs motor  
946 learning as analyzed by the rotarod assay (left, rotarod curve; right, slope of rotarod curve  
947 used as an index of the learning rate).

948 Data in panels D, F, and G are means  $\pm$  SEM. Statistical analyses were performed using  
949 unpaired t-test for D, F, and learning rate in G (\* $p < 0.05$ , \*\*\* $p < 0.001$ ) and repeat measures  
950 ANOVA for rotarod curve in G ( $F_{(1,19)} = 11.791$ , \*\* $p < 0.01$ ). Numbers of animals for each  
951 experiment are indicated in graphs.



952

953

954

**Figure 3: The *Clstn3* KO decreases inhibitory synapse numbers in the cerebellar cortex**

955

956

957

958

959

**(A)** Representative confocal images of cerebellar cortex sections stained for vGAT and tdTomato. Sections are from mice in which Purkinje cells were infected with control AAVs (Ctrl) or AAVs that induce the CRISPR-mediated *Clstn3* KO (red, AAV-encoded tdTomato signal; green, vGAT; ML, molecular layer; PCL, Purkinje cell layer; GCL, granule cell layer). Calibration bar applies to all images.

960

961

962


963

964

965

966

**(B-D)** The *Clstn3* KO in Purkinje cells suppresses the number of vGAT-positive synapses in the cerebellar cortex. Summary graphs show quantifications of the density (B) and size (C) of vGAT-positive puncta in the molecular layer (ML) of the cerebellar cortex (separated into deep and superficial areas), and of the vGAT-staining intensity in the Purkinje cell layer (PCL) and granule cell layer (GCL) of the cerebellar cortex (D). Data are means ± SEM (numbers of sections/mice analyzed are indicated in bar graphs). Statistical analyses were performed using unpaired t-tests, with \* $p < 0.05$ , \*\* $p < 0.01$ .



967

968 **Figure 4: The *Clstn3* KO decreases spontaneous inhibitory synaptic ‘mini’ events in**  
 969 **Purkinje cells**


970 **(A-C)** The *Clstn3* KO decreases the frequency but not the amplitude of mIPSCs (A,  
 971 representative traces; B, cumulative probability plot of the mIPSC amplitude [inset, average  
 972 amplitude]; C, cumulative probability plot of the mIPSC inter-event interval [inset, average  
 973 frequency]).

974 **(D)** The Purkinje cell *Clstn3* KO increases the rise but not decay time of mIPSCs.

975 **(E)** Plot of the number of mIPSC events vs. amplitude using a normal distribution.

976 **(F-H)** The *Clstn3* KO similarly impairs mIPSCs with a larger (>60 pA) and a smaller  
 977 amplitude (<60 pA), which in Purkinje cells are likely generated primarily by basket-cell and  
 978 stellate-cell synapses, respectively (F & G, summary graphs for the mIPSC amplitude (F)  
 979 and frequency (G) separately analyzed for high- and low-amplitude events; H, mIPSC rise  
 980 [left] and decay times [right], separately analyzed for high- and low-amplitude events).

981 All summary data are means  $\pm$  SEM. Numbers of cells/mice analyzed are indicated in bar  
 982 graphs. Statistical analyses were performed using unpaired t-tests (bar graphs with two  
 983 groups) or Kolmogorov-Smirnov test (cumulative analysis), with \*p<0.05, \*\*p<0.01,  
 984 \*\*\*p<0.001.



985

986

987

**Figure 5: The *Clstn3* KO decreases evoked inhibitory synaptic responses in Purkinje cells**


988 **(A)** Experimental design for recordings of IPSCs evoked by stimulation of basket cell axons  
 989 (ML, molecular layer; PCL, Purkinje cell layer; GCL, granule cell layer; PC, Purkinje cell;  
 990 Rec., recording patch pipette).

991 **(B & C)** The *Clstn3* KO decreases the amplitude of evoked basket-cell IPSCs (B,  
 992 representative traces of pairs of evoked IPSCs with a 50 ms inter-stimulus interval; C,  
 993 summary graphs of the amplitude of the first IPSC).

994 **(D & E)** The *Clstn3* KO in Purkinje cells does not affect the release probability at inhibitory  
 995 synapses as judged by the coefficient of variation (D) and the paired-pulse ratio with an  
 996 interstimulus interval of 50 ms (E) of evoked IPSCs.

997 **(F)** The *Clstn3* KO in Purkinje cells has no significant effect on IPSC kinetics (left, rise times;  
 998 right, decay times of evoked IPSCs).

999 All summary data are means  $\pm$  SEM. Numbers of cells/mice analyzed are indicated in bar  
 1000 graphs. Statistical analyses were performed using unpaired t-tests, with \*p < 0.05.



1001

1002

1003

1004

**Figure 6: CRISPR-mediated *Clstn3* deletion in the cerebellar Purkinje cells increases parallel-fiber excitatory synapse numbers without changing climbing-fiber synapse numbers**

1005

1006

1007

1008

1009

**(A & B)** Immunostaining of cerebellar cortex sections with antibodies to vGluT1 as a presynaptic marker for parallel-fiber synapses reveals a significant increase (A, representative confocal images from control and *Clstn3* KO mice [green vGluT1; red, tdTomato]; B, summary graphs of the vGluT1 staining intensity in the superficial (0-40%) and deep (40-80%) molecular layers of the cerebellar cortex).

1010

1011

1012

1013

1014

**(C & D)** Immunostaining with antibodies to GluA1, an astroglial marker for tripartite parallel-fiber/Bergmann glia synapses, also uncovers a significant increase in staining intensity (C, representative confocal images from control and *Clstn3* KO samples [green vGluT1; red, tdTomato]; D, summary graphs of the GluA1 staining intensity in the superficial (0-40%) and deep (40-80%) molecular layers of the cerebellar cortex).

1015


1016

**(E-G)** Immunostaining for vGluT2 as a marker for climbing-fiber synapses in cerebellar cortex fails to uncover a *Clstn3* KO-induced change (E, representative confocal images



1017 [green, vGluT2; red, tdTomato]; F & G, summary graphs of the density (F) and size (G) of  
1018 vGluT2-positive synaptic puncta in the superficial (0-40%) and deep (40-80%) molecular  
1019 layers of the cerebellar cortex).

1020 All numerical data are means  $\pm$  SEM; numbers of sections/mice analyzed are indicated in  
1021 the first bar graphs for each experiment. Statistical significance was assessed by unpaired  
1022 Student's t-test (\* $p < 0.05$ , \*\* $p < 0.01$ ).



1023

1024

1025

1026


**Figure 7: Morphological analysis of individual Purkinje cells reveals that the *Clstn3* KO robustly increases their dendritic spine density without significantly altering their dendritic arborization**

1027 **(A & B)** Biocytin filling of individual Purkinje cells via a patch pipette demonstrates that the  
1028 *Clstn3* KO does not significantly change the overall dendritic architecture of Purkinje cells  
1029 (A, representative images of Purkinje cell dendritic trees for control and *Clstn3* KO mice  
1030 after 3D reconstruction [for more images, see Supplementary Fig. S6]; B, quantifications of  
1031 the dendritic tree length [top] or dendritic arborization using Sholl analysis [bottom]).

1032 **(C-F)** The *Clstn3* KO increases the density of dendritic spines of Purkinje cells in the  
1033 superficial part of the cerebellar cortex (C & D, representative images of spiny dendrites at  
1034 low and high magnifications, respectively; [blue, red, and yellows arrowheads mark  
1035 different spine types]; E & F, summary graph [E] and cumulative distribution of the spine  
1036 density [F]).

1037 **(G)** The *Clstn3* KO in Purkinje cells increases preferentially the density of thin spines in the  
1038 superficial part of the cerebellar cortex, based on a morphological classification of spine  
1039 types into thin, stubby and mushroom spines.

1040 All data in B, E, and G are means  $\pm$  SEM; 6 control and *Clstn3* KO Purkinje cells were  
1041 reconstructed for B; numbers in the first bars of E indicate the number of cell/animal  
1042 analyzed for E-G. Statistical significance (\* $p < 0.05$ ; \*\* $p < 0.01$ ) in B and G was assessed by  
1043 an unpaired t-test, and in E by one-way ANOVA ( $F_{(3, 35)} = 5.693$ ,  $p = 0.003$ ), followed by  
1044 Tukey's post hoc comparisons for control and *Clstn3* KO groups.



1045

1046 **Figure 8: The *Clstn3* KO in cerebellar Purkinje cells increases the amplitude and**  
 1047 **frequency of parallel-fiber mEPSCs**

1048 **(A-C)** The *Clstn3* KO increases the amplitude and frequency of mEPSCs in Purkinje cells  
 1049 (A, representative traces; B, cumulative probability plot of the mEPSC amplitude [inset,  
 1050 average amplitude]; C, cumulative probability plot of the mEPSC inter-event interval [inset,  
 1051 average frequency]).


1052 **(D)** The *Clstn3* KO in Purkinje cells has no effect on mEPSC kinetics (left, mEPSC rise  
 1053 times; right, mEPSC decay times).

1054 **(E)** Expanded trace of averaged mEPSCs to illustrate the kinetic similarity of control and  
 1055 *Clstn3* KO events with a change in amplitude.

1056 **(F & G)** mEPSCs with slow rise times (>1 ms) and that are likely exclusively derived from  
 1057 parallel-fiber synapses exhibit the same phenotype as the total mEPSCs (same as B & C,  
 1058 but for mEPSCs with slow rise times).

1059 **(H)** The *Clstn3* KO in Purkinje cells has no effect on the kinetics of mEPSCs with slow rise  
 1060 times (left, mEPSC rise times; right, mEPSC decay times).

1061 All numerical data are means  $\pm$  SEM. Statistical significance with two groups was assessed  
 1062 by unpaired t-test (\*p < 0.05, \*\*p < 0.01), with the number of cells/mice analyzed indicated  
 1063 in the first bar graphs for each experiment. Cumulative analysis was done with  
 1064 Kolmogorov-Smirnov test (\*\*\*p < 0.001).



1065

1066

1067

**Figure 9: *Clstn3* KO in Purkinje cells elevates parallel-fiber synaptic strength, while leaving climbing-fiber synaptic strength unchanged**

1068

1069

**(A)** Schematic of the recording configuration for monitoring evoked EPSCs induced by parallel-fiber (PF-PC) and climbing-fiber stimulation (CF-PC) in Purkinje cells.

1070

1071

1072

**(B-D)** The postsynaptic *Clstn3* KO robustly increases the input/output relation of parallel-fiber synapses (B, representative traces; C, input/output curve; D, summary graph of the slope of the input/output curve determined in individual cells).

1073

1074

1075

1076

1077

**(E-G)** The postsynaptic *Clstn3* KO in Purkinje cells has no effect on presynaptic release probability as assessed by monitoring the coefficient of variation of evoked EPSCs (E, separately analyzed for different stimulus strengths) or the paired-pulse ratio (F, sample traces; G, plot of the paired-pulse ratio of parallel-fiber EPSCs as a function of interstimulus interval).

1078

1079

1080

1081

1082


1083

**(H-L)** The *Clstn3* KO has no effect on the amplitude, coefficient of variation, paired-pulse ratio, or kinetics of climbing-fiber synapse EPSCs (H, representative traces of climbing-fiber EPSCs elicited with an interstimulus interval of 50 ms; I & J, amplitude (I) and coefficient of variation (J) of evoked climbing-fiber EPSCs; K, plot of the paired-pulse ratio of climbing-fiber EPSCs as a function of interstimulus interval; L, rise [left] and decay times [right] of evoked climbing-fiber EPSCs).

1084 All numerical data are means  $\pm$  SEM. Statistical analyses were performed by two-way  
1085 ANOVA followed by Tukey's post hoc correction (C, G, K; for C,  $F_{(1, 150)}=35.83$ ,  $p<0.0001$ )  
1086 or unpaired t-test for experiments with two groups (D, E, I, J, L), with \* $p<0.05$ , \*\* $p<0.01$ .

1087  
1088  
1089

## SUPPLEMENTARY INFORMATION




1090

1091 **Figure S1: CRISPR-mediated deletion of Clstn3 does not cause a major change in the**  
1092 **levels of Clstn1/2 protein in cerebellum**

1093 **(A)** Representative immunoblot of cerebellar homogenates from mice that were  
1094 stereotactically injected in the cerebellum with Clstn3 CRISPR-KO or control AAVs. Note  
1095 that the antibody used has innumerable non-specific crossreactivities, but that the bands  
1096 identified as representing the combination of Clstn1 and Clstn2 (Clstn1/2) were previously  
1097 validated for this antibody (Um et al., 2014).

1098 **(B)** Summary graph of the Clstn1/2 protein levels in control cerebellum and cerebellum with  
1099 the Clstn3 KO. Data are means  $\pm$  SEM (n = 5 mice). An unpaired t-test revealed no  
1100 statistically significant difference between control and Clstn3 KO mice.

Potential genome editing pattern




Sg66 potential off-target effects

**C**

Sg66 predicted off-target sites

No.	Chromosome	Strand	Position	Pattern	Type
1	chr7	1	143748794	AGAGTACCAGGGCATTG <b>G</b> CA	Intergenic
2	chr2	-1	167750018	AG <b>G</b> GAACCAGGGCATTGTCT	Intergenic
3	chr13	-1	34933982	<b>T</b> TAGAACCATGGCATTGTCA	Intergenic




Sg21 potential off-target effects

**E**

Sg21 predicted off target sites

No.	Chromosome	Strand	Position	Pattern	Type
1	chr17	1	26570165	TGGATCTGGG <b>C</b> TACCCTTTG	Intergenic
2	chr5	-1	119991690	<b>G</b> GGAGCTGGTGTACCCTTCC	Intergenic
3	chr13	1	51347015	AGGATCT <b>A</b> GAGTACCCTTCA	Intergenic



1101


1102 **Figure S2: Predicted genome editing patterns by the sgRNAs used for the *Clstn3* KO**  
 1103 **in the current study and analysis of potential off-target effects of the sgRNAs using**  
 1104 **genomic sequencing of targeted *Clstn3* KO cerebellum**

1105 **(A-B)** Predicted genome editing effects for sg66 (A) and sg21 (B).

1106 **(C & D)** The three top-ranked potential off-target sites for sgRNA66 as analyzed by  
 1107 sequence predictions (C), and their analysis by genomic sequencing of *Clstn3* KO  
 1108 cerebellum, demonstrating no obvious gene editing effects on all three sites (D). Arrow  
 1109 indicates potential cutting positions.

1110 **(E & F)** Same as C & D, but for sgRNA21.





1111


1112 **Figure S3: The *Clstn3* KO in the cerebellum does not significantly affect sociability**  
 1113 **and social novelty in mice as measured using the 3-chamber social behavior test**

1114 **(A)** Control and *Clstn3* KO mice exhibited the same exploration behavior of the left and right  
 1115 chambers during the habituation period.

1116 **(B & C)** When exposed to a non-familiar ‘stranger’ mouse in one of the outer chambers,  
 1117 cerebellar *Clstn3* KO mice exhibited a lower degree of interactions with the stranger mouse  
 1118 but this was not statistically significant (B, the time that the test mouse spent in the  
 1119 chambers with empty cup or ‘stranger1’ mouse; C, sociability index).

1120 **(D & E)** When given the choice between exploring a ‘stranger 1’ mouse to which it was  
 1121 previously exposed (see B), or a ‘stranger 2’ mouse that is novel, both control and  
 1122 cerebellar *Clstn3* KO mice prefer the novel mouse for interactions (D, the same as B,  
 1123 except empty cup has ‘stranger2’; E, social novelty index).


1124 All data are means ± SEM. Paired t-tests were applied to analyze the statistical significance  
 1125 of parameters within the same group, and unpaired t-tests to compare between control and  
 1126 *Clstn3* KO groups at sociability index and social novelty index analysis, \*p<0.05.



1127

1128 **Figure S4: Capacitance and membrane resistance of Purkinje cells are unaffected by**  
 1129 **the *Clstn3* KO**


1130 **(A-E)** Summary graphs of the capacitance (left) and input resistance (right) of Purkinje cells  
 1131 determined during the recordings described in Fig. 5 and 6. All data are means ± SEM.  
 1132 Statistical analyses were done with unpaired t-test,  $p > 0.05$ .



1133

1134 **Figure S5: Analysis of the kinetics of large (>60 pA) and smaller (<60 pA) mIPSCs**  
 1135 **confirm that larger mIPSCs that are presumably generated by basket-cell synapses**  
 1136 **closer to the soma have faster rise times but slower decay times**

1137 **(A & B)** Rise (A) and decay times (B) of large and smaller mIPSCs examined in the same  
 1138 Purkinje cells. All data are means  $\pm$  SEM. Statistical analyses were performed with paired  
 1139 t-test, \*\*\* $p < 0.001$ .




1140

1141 **Figure S6: Images of individual reconstructed biocytin-filled Purkinje cells, and**  
 1142 **further quantifications of the morphological properties of spines from control and**  
 1143 ***Clstn3* KO Purkinje cells**

1144 **(A & B)** Images of all reconstructed Purkinje cells, as performed using NeuroLucida360  
 1145 software in control and *Clstn3* KO cerebellar cortex.

1146 **(C & D)** Quantification of various spine parameters in the superficial (C) and deep layers (D)  
 1147 of control and *Clstn3* KO mice (left, head width; middle left, neck length; middle right, neck  
 1148 width; right, head/neck ratio). Data are means  $\pm$  SEM. 5-8 spines were analyzed per layer  
 1149 per cell; the numbers of cells/mice examined are indicated in the left bar graph. Statistical  
 1150 analyses were performed with unpaired Student's t-tests,  $p > 0.05$ .



1151

1152

1153

1154

**Figure S7: Summary of synaptic changes induced in Purkinje cells by the *Clstn3* KO.** The Purkinje cell image is from one of the cells reconstructed during the present study. The changes summarized on the right were identified in Figures 3-9.